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Abstract
Cancer therapy benefits today from the availability of new promising classes of drugs such as
therapeutic proteins. Due to their ability to specifically bind targets in the body they allow to
modulate specific chemical reactions and ultimately to modify the functional response of the
cell, such as cell growth or cell division. Targeting receptor systems by competitive inhibition
is the objective of various protein drugs in development and on the market. Many targeted
receptor systems also constitute a degradation mechanism for the drug via endocytosis and a
thorough understanding of the complex interplay between the drug’s pharmacokinetics and
its effect, is largely missing.
For complex diseases such as cancer, systems biology models of therapeutically relevant
cellular processes have proven valuable for identifying potent drug targets. So far, such
information about the dynamics of the targeted system is neglected in later stages of the drug
development process when pharmacokinetic modeling is used to guide dose finding and analyze
preclinical or clinical in vivo data. This is especially critical for therapeutic proteins where,
due to the degradation mediated by the targeted receptor, drug effect and pharmacokinetics
are inherently interdependent.
This thesis combines the points of view of systems biology and pharmacokinetics. We
present a detailed mechanistic model of the targeted cellular system that explicitly takes into
account receptor binding and trafficking inside the cell and that is used to derive reduced
models of drug degradation which retain a mechanistic interpretation. By integrating cell-
level models with established pharmacokinetic models, we translate biophysical properties
of protein drugs into a transient drug effect in vivo. We illustrate the approach for anti-
bodies against the epidermal growth factor receptor used in cancer therapy. The cell-level
pharmacokinetic/pharmacodynamic model identifies options and limits for future therapeutic
antibodies and links their inhibitory effect with genomic alteration of tumor cells.
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1 Introduction
1.1 Cancer drug development today
Cancer medicine is rapidly changing. Recent advances in many different disciplines like
chemotherapy, hormone therapy, radiotherapy and diagnostic imaging have improved our
understanding of cancer and the clinical practice. The current view on cancer development
envisions cells undergoing a series of genetic alterations which results in the six hallmarks of
cancer: (i) self-sufficiency in growth signals, (ii) insensitivity to antigrowth signals, (iii) eva-
sion of programmed cell death, (iv) limitless replicative potential, (v) sustained angiogenesis,
and (vi) tissue invasion and metastasis [50]. Since each of these alterations confers a growth
advantage, the progressive conversion of normal human cells into cancer cells is thought of
resembling Darwinian evolution [104]. Cancer therapy today is particularly influenced by
the ability of molecular cell biology to elucidate the detailed cellular processes involved in
each of these steps of cancer development. This is nicely illustrated by the development
of the drug Imatinib (Gleevec/Glivec) against a form of cancer called chronic myelogenous
leukemia (CML). CML is characterized by the alteration of a single gene, termed Bcr-Abl
whose expressed protein shows enhanced tyrosine kinase activity [116, 33]. This molecular
understanding of CML secondary allowed the development of Imatinib as an inhibitor to
the enzyme Bcr-Abl. Imatinib, in the majority of patients, leads to a normalization of the
blood cells within 3 weeks of initiation of therapy[33]. The high efficacy of Imatinib can be
attributed to the identification of Bcr-Abl as a fragile node in the cancer mediating signalling
cascade which only exists in target cells [65]. Imatinib and the underlying understanding of
the genetic and biochemical processes therefore “converted a fatal cancer into a manageable
chronic condition”1.
Such a success stimulated the development of many therapies guided by validated effects on
a defined molecular target [44, 27, 120, 37, 100, 103, 61]. Although different target therapies
have made it to the clinical practice, the development of good rational drugs remains extremely
difficult and the overall rate of new drug approvals has failed to keep pace with ever-increasing
spending on pharmaceutical research [29, 32, 59, 75, 70]. The story of Imatinib was probably
more an exception than a role model for the development of potent cancer drugs, or as Fishman
and Porter called it, it was “a low-hanging fruit” [38]. In other situations, instead of focusing
on a single hyperactive/underactive protein, this protein has to targeted in the context of
1The Lasker DeBakey Clinical Medical Research Award 2009
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its cellular network. These signalling pathways are triggered by external stimulus, sensed by
the cell through cell-surface receptors [63]. The activation of such receptors is translated by
signalling pathways into a specific change in gene expression. Gene activation or suppression
ultimately leads then to a change in the cell’s behavior. Examples for such functional responses
of the cell to the external stimulus are changes in its ability to grow or differentiate, and to
undergo division or self-destruction. As examples, Fig. 1.1 depicts the core components of five
signaling pathways where a misregulation of several of these components is directly associated
with cancer development. The dynamics occurring in such signalling networks, including
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Figure 1.1: Receptor tyrosine kinase (RTK) receptor, E-Caherin, Frizzled, transforming growth factor-
β receptor (TGF-βR) and cytokine receptor receptor are examples for receptors which stimulate sig-
nalling pathways modulating gene expression and cell proliferation. The arrows and T-bars describe
an activation and inhibition, respectively. For simplicity, only the core elements of the pathways are
depicted here. The elements of the different pathways follow descriptions of signalling cascades in
Hanahan and Weinberg [50], Klipp and Liebermeister [66], and Kumar et al. [78].
circular dependencies (such as the negative feedback from MAPK to SOS in Fig. 1.1), differ
substantially from the current view on drug development which “ at its core, [...] seeks to
define a linear pathway, or causal chain, leading to disease, and then to interfere at one of
these steps – by inhibiting a crucial enzyme or blocking an important receptor, for example”
[126].
Hence, understanding signalling pathways is crucial in cancer research. Due to their com-
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plexity it becomes evident that for a successful development of cancer drugs reliable pre-
dictions of the impact of perturbations of the network are vital. When analyzing complex
systems in engineering, the use of mathematical modelling has been proven useful. Mathe-
matical models allow to connect knowledge about individual parts and formulate hypothe-
ses about the behavior of the sum of these parts. To overcome the limitations of current
drug development strategies and to increase the success rate when developing new drugs
the integration of mathematic modelling into the development process has been advocated
[17, 65, 148, 18, 26, 39, 58, 92]. Indeed, mathematical analysis can demonstrate that living
systems may exhibit an intrinsic robustness against various perturbations and hence many
potential drugs that specifically target a particular protein (which is considered to underlie a
given disease) have been found to be less effective than hoped [65].
Cell-level kinetic models are a language to analyse the robustness of a response to a drug
and therefore can identify and rank potential targets in cellular networks [65]. Hence, com-
putational models are of increasing relevance for target identification in drug discovery [58].
A recent prominent example is the use of a kinetic model to identify critical components in
the ErbB receptor family mediated signaling pathways [20], an important pathway for cancer
development. As a result, a therapeutic antibody was developed which targets the ErbB3
receptor and is currently in early clinical trials [130].
In the patient, the time trajectory of the drug concentration is a critical component of
drug efficacy [111]. Therefore, in addition to the increasing level of detail of systems biology
models, there exists a great need to place cell-level models in the context of the condition in
vivo [111, 109, 1]. Hence, the shift from a “target-centric” to a “biochemical network-centric”
view of drug development alone is unlikely to be sufficient to predict the in vivo effect in the
complex human system.
Another aspect is that after the target was identified, in the later stages of the drug develop-
ment process prior knowledge about the targeted system is invariably ignored when analyzing
preclinical or clinical data [80]. As a result, knowledge about the dynamics of the target in
vitro cannot be used in later stages of the drug development, where knowledge about drug
disposition in vivo has been obtained. Such knowledge is usually in the drug development
process described by pharmacokinetic/ pharmacodynamic models.
This thesis advocates to integrate the pharmacokinetics and pharmacodynamics of the
studied drug into the systems view on its effect. Second, we propose to use more mechanistic
information about cellular processes when analyzing clinical data in the later stages of drug
development.
Current pharmacokinetics describes absorption, distribution, metabolism, and excretion
of a drug in the body using empirical or semi-empirical models of the processes involved.
In contrast to systems biology, current pharmacokinetic modelling (with the exception of
physiologically based pharmacokinetic models discussed in section 5.1) is mostly a top down
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approach, which relates observations to models, selected based on, e.g., established statistical
criteria (such as maximum likelihood), the precision of estimates of model parameters, and
in few cases on model evaluation techniques [35, 137, 135, 136]. However, being empirical in
nature, these models do not provide a mechanistic understanding of, for example, how the
different processes of receptor trafficking contribute to the overall pharmacokinetic profile.
We think, combining systems biology and pharmacokinetic models is particularly useful
for the optimization and development of a relatively new class of drugs, therapeutic proteins.
The therapeutic potential of proteins results from their ability to bind—with high affinity—to
specific targets such as cell-surface receptors.
In recent years, therapeutic proteins have been a major focus of research and develop-
ment activities in the pharmaceutical industry [93]. Currently, approximately 100 therapeu-
tic proteins have been approved for human use, most of them being biotechnology-derived
drug products and many more are under development [93]. Important classes of therapeutic
proteins are monoclonal antibodies, growth factors, and cytokines. Generally, therapeutic
proteins provide highly attractive but sometimes exceptional behavior in the body [76]. The
largest class of therapeutic proteins developed today are therapeutic monoclonal antibodies
(mAbs). Antibodies can interfere with specific cellular targets and signaling pathways and
have demonstrated their potential in therapies for cancer and other complex diseases [94].
Therapeutic antibodies are produced by immunization of a mouse with a specific antigen.
The subsequent immune reaction of the mouse leads to the production of antibody producing
B lymphocytes which accumulate in the spleen [94]. These cells are capable of producing
the corresponding antibody to the administered antigen, but for the production of larger
quantities of the antibody those B lymphocytes have to be fused with malignant myeloma
cells to form immortal cells, called hybridomas. This technique was developed by Koehler
and Milstein [69] and for this discovery they were awarded the 1984 Nobel prize for medicine.
Because the produced antibodies by those hybridoma cells are cloned from only one original
B lymphocyte, and hence are identical, they are also called monoclonal Antibodies (mAbs).
The use of rodent systems to produce mAbs however prevented their use in indications
in humans where prolonged dosing was required due to their high immunogenicity [82]. To
overcome this limitation chimeric, humanized, and fully human mAbs have recently been
developed.
Chimeric mAbs are developed by exchanging the regions of the human antibody genes
for those derived from the mouse which generates chimeric genes. These genes are then
introduced into eukaryotic cells which can produce chimeric antibodies that are about 70%
human [150]. For fully human antibodies the mouse from which the B lymphocyte is derived is
genetically engineered. First, the antibody gene clusters are inactivated which prevents those
mouse from producing antibodies and mature B lymphocytes. Subsequently, DNA segments
containing large parts of the human gene clusters are introduced into the mice which, after
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being immunized with any target, enables them to produce high affinity antibodies [150]. Since
the antibodies are produced from the human antibody genes after fusing the B lymphocyte
with myeloma cells the resulting hybridomas cells produce fully human monoclonal antibodies.
Trastuzumab (Herceptin) was the first antibody for the treatment of cancer approved by
the Food and Drug Administration (FDA) in 1998. It created great interest in the scientific
community as well as outside 2. Trastuzumab is an anti-Her2 antibody used in the treatment
of breast cancer against tumors overexpressing the Her2 receptor. The development followed
the identification of the oncogene Her2/neu in 1984 [127] and its cloning [131, 22]. In 1986
Drebin, Link, Weinberg, and Greene demonstrated that an anti-HER-2 monoclonal antibody
is able to inhibit Her2/neu transformed cells [31] and the following clinical studies found
that this antibody, trastuzumab, halves the risk of tumor recurrence which corresponds to an
absolute increase in 4-year disease free survival (DFS) of 17% [110].
Other antibodies against receptors of the ErbB family on the market are Cetuximab (Er-
bitux) and Panitumumab, which inhibit the epidermal growth factor receptor (EGFR). Ce-
tuximab is currently approved for the treatment of colorectal cancer and squamous cell carci-
noma of the head and neck, Panitumumab for colorectal cancer. Additionally, three anti-ErbB
antibodies are in late clinical phases (Nimotuzumab, Zalutumumab, IMC-11F8) [107].
Due to their similarity to endogenous proteins, after binding to their cell surface target,
many protein drugs and especially antibodies are internalized into the cell by Receptor Medi-
ated Endocytosis (RME)[90, 141, 138]. Within the cell, the complex may be recycled to the
cell surface or intracellularly be cleaved [121, 139]. RME therefore mutually links the effect
of a therapeutic protein with its pharmacokinetics. As a consequence, the design and the
biophysical optimization of therapeutic proteins based on cell-based assays and preclinical
pharmacology, becomes a considerable challenge [111].
One example of a biophysical property of a therapeutic protein affecting both, the cel-
lular therapeutic effect and the PK, is the affinity of therapeutic antibodies to their tar-
get. Currently, mAbs on the market have a high receptor affinity in the sub-nM range,
but the traditional design criterion that “the best binder makes the best drug” has been
questioned[111, 24, 19]. To date, no model exists which predicts both, the pharmacokinet-
ics and the inhibitory effect of therapeutic proteins [109] and can guide the optimization of
biophysical properties of therapeutic proteins.
1.2 Objective of the thesis
This thesis systematically investigates the dependencies between systemic pharmacokinetic
models and cell-level kinetic models. First, we examine how pharmacokinetic models can
be improved when incorporating cell-level dynamics. This extends current pharmacokinetic
2the discovery of Trastuzumab by Dr. Dennis Slamon and others at UCLA was made into the film Living
Proof, directed by Dan Ireland.
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models and gives a rationale in which situations this extended model or already available
pharmacokinetic models should be used. Second, we analyze cell-level kinetic models of
antibody action under the conditions of a typical in vitro experiment. We investigate how drug
properties influence the potential of the antibody to inhibit the activation of the epidermal
growth factor receptor which mediates a variety of malicious cellular responses of cancer cells
such as proliferation, differentiation, survival, and angiogenesis [96]. As the final step, we
combine the in vivo and in vitro models into a cell-level pharmacokinetic/pharmacodynamic
model. This model allows to integrate preclinical pharmacokinetic data and to investigate the
biochemical properties of antibodies currently used in cancer therapy under in vivo conditions.
Using this model, we identify options and limits for the optimization of efficacy and tumor
selectivity of future therapeutic antibodies.
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1.3 Thesis organization
In a more detailed summary, we will perform three steps to mechanistically model the phar-
macokinetics and the inhibitory effect of antibodies used in cancer therapy.
In Chapter 2 we develop a detailed mechanistic models of the binding of therapeutic
proteins to targets on a cells surface as well as subsequent intracellular processes of antibody
degradation. We then reduce this mechanistic model to resemble empirical models currently
used in the analysis of clinical pharmacokinetic data. The mechanistic derivation of the
empirical models allows us to give a rationale in which situations to use the different models.
Further, the reduction of the detailed model connects the processes on a cell-level with the
effective dynamics on a whole body level usually determined in pharmacokinetic studies.
Chapter 3 investigates the inhibitory effect of therapeutic antibodies on the epidermal
growth factor receptor under the conditions of a typical in vitro experiment. The action of
the drug is studied in the presence of the natural ligand by extending an established model of
receptor activation. The model is used to translate biophysical properties of the antibody, like
the affinity, into a transient inhibitory effect and to predict tumor cell selectivity. Further,
under the in vitro conditions an analytical study of the receptor system allows to derive an
exact formula for the cumulative antagonistic effect of therapeutic antibodies and identifies
the synthesis rate of the receptor as the critical parameter of the cellular system regarding the
inhibitory effect of the drug. Also, we investigate drug action in a closed microenvironment of
a tumor cell where the exchange of molecules with the surrounding is limited. This identifies
ligand accumulation as a potential counter response to the drug action in such a closed system.
In Chapter 4, we develop a strategy to include a cell-level model into a whole body model
of drug disposition. We use the relations between the cell-level processes and the effective
dynamics on the whole body level determined in Chapter 2. This allows us to estimate
the number of target expressing cells which come in contact with the drug. This number
facilitates the integration of cell-level kinetics into a systemic pharmacokinetic model because
the impact of a single cell can be scaled up to an impact on the whole body level. As in
Chapter 3 we investigate the properties of therapeutic antibodies regarding their antagonistic
effect on the epidermal growth factor receptor, but here under conditions which reflect the
conditions in vivo more closely than the in vitro setting. This allows us, for the first time, to
study the optimization of biophysical properties of therapeutic proteins by coupling cellular
dynamics of the target with the drugs disposition in the body.
A final comment to the models the reader will find in the different chapters. The
systemic pharmacokinetic model will be the same in the different parts of the thesis. The
rationale of this is that the used two-compartment model has been found useful by many
authors for analyzing preclinical/clinical pharmacokinetic data of protein drug trials [30, 77,
101, 67, 147]. In contrast, we use different cell-level models in the different chapters.
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Figure 1.2: Illustration of the different cell-level models used in the thesis.
Fig. 1.2 illustrates the different cell-level models of receptor activation, inhibition and traf-
ficking used in this thesis. Model 1 is used to structurally characterize the impact of the
cell surface/intracellular processes on the pharmacokinetics. Model 2 and 3 lump different
processes of receptor trafficking. These descriptions of receptor activation and trafficking
are in correspondence with established models in the literature [158, 156, 161, 159, 133] and
provide experimentally determined parameter values [68, 53, 55, 54, 140] which allows us to
make quantitative predictions. A more detailed justification of the different cell-level models
is given in the different chapters (see section 2.5, 3.2, and 4.1) and their ability to act as an
interface to detailed models of signalling cascades is discussed in Chapter 5.
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2 The influence of cell level dynamics on
pharmacokinetics
In the Introduction we discussed the interdependence of the pharmacokinetics and the in-
hibitory effect of therapeutic proteins because of RME. In this Chapter, we develop a detailed
model of RME to study the impact of antibody binding and receptor dynamics on the phar-
macokinetics of the drug. In the following Sections 2.1–2.3 some basic concepts of current
pharmacokinetic modelling techniques for therapeutic proteins are presented. These concepts
and techniques will subsequently be used to derive reduced models of RME which still al-
low for a mechanistic interpretation of the parameters and can be used to analyse clinical
pharmacokinetic data.
2.1 The pharmacokinetics of therapeutic proteins
Frequently, it is said that pharmacokinetics (PK) is what the body does to the drug, and
pharmacodynamic (PD) is what the drug does to the body. Pharmacokinetic is subdivided
into the absorption of the drug, its distribution in the body, metabolic processes, and the
elimination of the drug.
Therapeutic proteins are usually administered intravenously, subcutaneously, or intramus-
cularly due to gastrointestinal enzymatic degradation and poor permeability of the gastroin-
testinal mucosa [94]. Studying absorption is therefore usually not necessary in pharmacoki-
netic studies of therapeutic proteins [90]. The distribution of therapeutic proteins is deter-
mined by their biophysical properties. Due to their large size (> 1000 Da) the distribution
through membranes into peripheral tissues is limited. Protein drugs with a size above the
glomerular filtration limit (> 60 kDa) are not significantly excreted by the kidney [94], which
contributes to the large halflife of many therapeutic proteins in the body. Also their distri-
bution in the body is typically limited to the extracellular space [114]. As discussed above,
one feature of protein drugs is their highly specific binding to epitopes expressed on certain
cells in the body. Besides the proteolysis by proteases and peptidases in the blood, liver, kid-
neys and gastrointestinal tissue, uptake subsequent to the binding to target receptors plays
a major role in the elimination of protein drugs from the body [90]. Because the number of
available target receptors and therefore the capacity of the cells to clear the drug from the
body is limited, receptor binding and RME is suspected to be a major source for the nonlinear
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pharmacokinetic behavior that is observed in clinical data for numerous protein drugs [141].
In conclusion, the pharmacokinetic of therapeutic proteins is distinct and can simply be
summarized as long halflife with nonlinear elimination kinetics. While the long halflife of
several weeks is seen as an advantage because it minimizes the occasions the drug has to
be injected into the patient, the nonlinearity is traditionally seen as complicating the dose
finding process.
2.2 Pharmacokinetic compartment models
When aiming at analyzing preclinical/clinical pharmacokinetic data of protein drug trials,
typically empirical 1-, 2- or 3-compartmental models including linear and/or nonlinear dis-
position processes have been developed. These models have been selected based on, e.g.,
established statistical criteria (such as maximum likelihood), the precision of estimates of
model parameters, and in few cases on model evaluation techniques [35, 137, 135, 136].
Compartment systems consist of a number of homogeneous, well-mixed, lumped subsys-
tems, called compartments, which exchange with each other the modelled drug. Depending
on the type of model the compartments represent specific physiological organs (like in physi-
ologically based pharmacokinetic models) or organs lumped due to e.g. their diffusibility for
the specific drug (like in empirical pharmacokinetic models) [46]. The amount of a drug in a
compartment, Ai, for a linear system with p compartments can be described by the following
equation [46]:
d Ai
dt
=
p∑
j=1,j 6=i
kijAj −
p∑
j=1,j 6=i
kjiAi − k0iAi + ui(t) , i = 1, 2, ..., p (2.1)
where Ai is the the amount of drug in the compartment i, kij is the rate constant describing
the transport to compartment i from compartment j, and k0i denotes the rate constant of
elimination of drug from the compartment i. Also the drug is administered to the compart-
ment, which is described with the flow ui(t).
Often instead of the amount, concentrations are determined and the systems has to incor-
porate the volumes of the p compartments Vp. Therefore the system changes to
d Ci
dt
=
p∑
j=1,j 6=i
QijCj −
p∑
j=1,j 6=i
QjiCi − CLiCi + ui(t) , i = 1, 2, ..., p (2.2)
with Qij = kij ·Vj , Cj = Aj/Vj , CLi = k0i ·Vi, and Ci = Ai/Vi. An illustration for the case of
linear elimination from the central compartment (p = 1) and an additional distribution into
a peripheral compartment (p = 2) is depicted in Fig. 2.1, a and b, respectively. The excretion
from the central compartment is proportional to the drug concentration in this compartment
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Figure 2.1: Pharmacokinetic compartment models. (a) One-compartment model with linear elimina-
tion. (b) Two-compartment model with distribution into a second compartment and metabolisation of
the drug. (c) Two-compartment model with linear elimination from the first compartment, distribution
into a second compartment with saturable elimination. The drug is administered into the compartment
with rate ui(t). In case of a bolus dose ui(t) is a delta distribution at t=0.
with the factor of proportionality CL called the clearance of the drug.
For therapeutic proteins the elimation capacity is often found to be nonlinear and Michaelis–
Menten terms have often been used to analyze experimental data in order to account for the
observed nonlinearity [30, 77, 102, 67, 147] (see Fig. 2.1, c).
2.3 Target-mediated drug disposition
As discussed above, protein drugs are developed to bind with high specificity to targets in
the body like enzymes, receptors, or transporters. In case that the amount of drug bound to
the target is significant compared to the given dose, the pharmacokinetics of the drug will be
influenced by the binding.
In PK/PD modeling, target mediated drug disposition (TMDD) has been proposed as a
general semi-mechanistic model for drugs that bind with high affinity to a pharmacologic
target [88]. Although originally developed to describe effects of extensive drug target binding
in tissues, TMDD has more recently gained interest as a model for saturable elimination
mechanisms for specific peptide and protein drugs, including RME [141, 87, 84, 155]. Recently,
TMDD was extended to the situation where the binding to the target happens much faster
than the other processes and therefore a quasi steady state assumption for the complex can
be assumed [89].
Although TMDD considers pharmacological target binding as the key process controlling
the complex nonlinear processes, particular features of receptor trafficking inside the cell are
11
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Figure 2.2: Pharmacokinetic model of target-mediated drug disposition.
not taken into account i.e., the process by which receptors and ligands are either targeted for
intracellular degradation or recycled to the surface for successive rounds of trafficking [55].
Second, whenever a drug molecule is degraded in the TMDD setting, both, a drug and a
receptor molecule are degraded. However, for many ligands, including TNF-α, degradation
of the drug does not necessarily imply degradation of the receptor, since the receptor can be
recycled [139].
2.4 Our approach to pharmacokinetic modelling of therapeutic
proteins
The presented compartment models are empirical in nature. Hence, these models do not
provide a mechanistic understanding of how the different processes of receptor trafficking
contribute to the overall pharmacokinetic profile, which is expected to guide, e.g., lead opti-
mization or the design of more efficient dosing regiments. TMDD models are semi-empirical in
the way that they include the binding of the drug but pool the different cell-level processes in
a process which happens at a whole body level. Therefore they do not provide a mechanistic
understanding of the processes as well. Equally important, there is no theoretical background
as to when to use the different existing empirical or semi-empirical models for describing the
nonlinear pharmacokinetic of therapeutic proteins.
In this Chapter, the objective is to develop a framework for RME that is specifically tailored
to the needs in PK analysis of clinical trials by bridging the points of view in pharmacokinetics
and systems biology.
The aims are (i) to develop a detailed model that takes into account the most relevant
processes in relation to receptor trafficking; (ii) to derive reduced models of RME which
retain a mechanistic interpretation and are defined in terms of a few parameters only, (iii) to
offer guidance as to when use them, and (iv) to analyze the impact of the different processes
on the extent of nonlinearity. While our approach applies to many receptor systems in general,
we will use the epidermal growth factor receptor (EGFR) signalling pathway to illustrate the
approach. The EGFR system has been intensively studied over the past 20 years and is one
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of the most important pathways for cell growth and proliferation as well as angiogenesis and
metastasis [85]. The EGFR system comprises a tyrosine kinase receptor, which is activated
by a variety of ligands such as the epidermal growth factor (EGF) or the transforming growth
factor-α (TGF-α) [152, 153, 51]. Mathematical modelling of the EGFR system has proven
to be useful for both, measurement of rate constants [158] as well as to elucidate the effects
of receptor trafficking as an input to downstream signalling cascades [161, 133]. From a
therapeutic point of view, the EGFR system has shown to be a promising target in cancer
therapy [6, 7]. Several agents, including therapeutic proteins such as monoclonal antibodies
(mAbs), have been developed to specifically target the EGFR with some already approved
for drug treatment [5, 47, 112].
2.5 A detailed cell level model of receptor mediated endocytosis
There is a considerable amount of literature about detailed mechanistic descriptions of recep-
tor trafficking systems in the systems biology literature (see, e.g., [139, 161] and references
therein). Based on these receptor trafficking systems, our approach is to build a general de-
tailed mechanistic model of RME that takes into account the most relevant kinetic processes
of drug binding and receptor trafficking inside the cell. Detailed models derived from the
underlying biochemical reaction network have the advantage of a mechanistic interpretation
of the kinetic processes and estimated parameters. In [125], a cell-level model of the cy-
tokine granulocyte colony-stimulating factor (G-CSF) and its receptor was incorporated into
a pharmacokinetic/pharmacodynamic model to allow for analyzing the life span and potency
of the ligand in vivo. However, often these advantages come along with the disadvantage
of containing more parameters which, e.g., in population PK analysis of clinical trials may
result in poorer performance in the model selection process, since models containing more pa-
rameters are usually penalized by the corresponding model selection criteria. In this Section,
we present a detailed mechanistic model of RME that explicitly takes into account receptor
binding and trafficking inside the cell. This model is in the subsequent Sections used to derive
reduced models of RME which are suitable for PK analysis and at the same time retain a
mechanistic interpretation.
In the following description the term ’ligand’ refers to both, a physiological ligand as well
as an exogenous drug ligand, since the described processes are identical for both. We propose
the following detailed model of RME of a ligand as schematically represented in Fig. 2.3.
The ligand Lex is present in the extracellular space and reversibly binds to free receptor Rm
at the cell membrane with association rate constant kon to form the ligand-receptor complex
RLm that dissociates with rate constant koff . The complex is internalized with the rate
constant kinterRL forming an endosome. The internalized ligand-receptor complex RLi is either
recycled to the membrane with the rate constant krecyRL, degraded with the rate constant
13
2.5. A DETAILED CELL LEVEL MODEL OF RECEPTOR MEDIATED ENDOCYTOSIS
Vγ
Lex
Rm +
kon
koff
kinterRL
krecyRL
kbreak
krecyR kinterR
RLm
RLi
Ldeg
Ri
kdegR
ksynth
kdegRL
RLdeg
Figure 2.3: Schematic representation of the detailed model of receptor mediated endocytosis. See text
for description.
kdegRL to RLdeg, or dissociates with the rate constant kbreak. The dissociation results in the
subsequent degradation of the ligand Ldeg and the availability of the free receptor Ri inside
the cell. Free intracellular receptor Ri is recycled to the membrane with the rate constant
krecyR and free membrane receptor Rm is internalized with the rate constant constant kinterR.
Inside the cell, the receptor Ri is produced with the rate ksynth and degraded with the rate
constant kdegR.
Based on the law of mass action, the rates of change for the various molecular species are
given by the following system of ordinary differential equations (ODEs):
dLex/dt = koff ·RLm − kon/(VγNA) ·Rm · Lex (2.3)
dRm/dt = koff ·RLm − kon/(VγNA) ·Rm · Lex + krecyR ·Ri
−kinterR ·Rm (2.4)
dRLm/dt = kon/(VγNA) ·Rm · Lex − koff ·RLm − kinterRL ·RLm
+krecyRL ·RLi (2.5)
dRLi/dt = kinterRL ·RLm − kbreak ·RLi − krecyRL ·RLi
−kdegRL ·RLi (2.6)
dRi/dt = kinterR ·Rm − krecyR ·Ri + kbreak ·RLi − kdegR ·Ri
+ksynth (2.7)
where NA is Avogadro´s number and Vγ is the volume of extracellular space per cell. In
the above equations, all variables are expressed in number of molecules. All parameters
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are first-order rate constants in units [1/time] except for ksynth, which is a zero-order rate
constant in units [molecules/time], and kon which is a second-order rate constant in units
[1/(concentration·time)]. The factor 1/(VγNA) ensures conversion of units from molar con-
centration to number of molecules. With respect to the receptor, the above equations com-
prise the following three overall processes (cf. Fig. 2.3): (1) synthesis and degradation; (2)
distribution of the different receptor species within and between the cytoplasm and the cell
membrane, and (3) ligand-receptor interaction. With respect to the ligand, its disposition
processes consist of the three overall processes: (i) binding to the receptor; (ii) internalization
of the ligand-receptor complex; and (iii) intracellular degradation.
Table 2.1: Parameter values for the EGF/EGFR system. All parameter values have been extracted
from Hendriks et al. [55, 53] and Shankaran et al. [133]. See also Section “RME for the EGF/EGFR
system”.
Parameter Unit Value
1 kon nM
−1 · h−1 5.82
2 koff h
−1 14.4
3 R
(SS)
m molecules 2 · 105
4 krecyR h
−1 3.84
5 kinterR h
−1 4.2
6 kdegR h
−1 0.96
7 krecyRL h
−1 1.2
8 kinterRL h
−1 15
9 kdegRL h
−1 1.2
10 Vγ l · cell−1 4 · 10−10
The detailed model and its subsequent derived reduced versions will be analyzed using
experimentally measured parameters for the degradation of the epidermal growth factor,
binding to the epidermal growth factor receptor and subsequent internalization [55, 53]. The
rate constants of the corresponding reactions are listed in Table 2.1.
Hendriks et al. [55, 53] explored EGF as ligand to measure rate constants of the EGFR
system. However, not all rate constants of the herein proposed detailed model of RME were
explicitly measured in [55, 53]. Since EGF is predominantly degraded from the EGF-receptor
complex [139] rather than from the free form, we set kbreak = 0 resulting in klyso = kdegRL 6= 0 .
Since the parameter ksynth was not available in literature, we used the steady state assumption
for the receptor system prior to any ligand administration and the experimentally measured
steady state number of membrane receptor R
(SS)
m [133] to determine ksynth using the relation
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ksynth = kdegR · R(SS)i with R(SS)i = R(SS)m · kinterR/krecyR. The initial number of receptors
are Rm(0) = R
(SS)
m , Ri(0) = R
(SS)
i , and RLm(0) = RLi(0) = 0; the initial concentration of
extracellular ligand is Lex(0) = 40 nM.
2.6 Model reduction
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Figure 2.4: Models of receptor mediated endocytosis of different resolution: Detailed model (Model
A), reduced model of saturable distribution into the receptor system with linear degradation (Model B),
and reduced model of saturable degradation (Model C). See text for details.
One objective of this study is to derive and analyze reduced models of RME that capture the
impact of receptor dynamics on the distribution and elimination of a ligand and that still allow
for a mechanistic interpretation. While during short time intervals the transient redistribution
processes between the different receptor speciesRm, RLm, RLi andRi may be of interest, these
are usually assumed to be negligible on time scales of interest in pharmacokinetics. Therefore,
our approach to reduce the detailed RME model will be based on the assumption that the
receptor species Rm, RLm, RLi and Ri are in quasi-steady state. In order to finally derive
reduced models of RME, it is necessary to make an additional assumption on the time-scale of
receptor synthesis and degradation. We distinguish the following two scenarios: (1) the time
scale of receptor synthesis and degradation is slow in comparison to the time scale of ligand
disposition. In this case, we formally set ksynth = kdegR = kdegRL = 0. As a consequence,
the total number of receptors in the system remains constant. Or, (2) the time scale of
receptor synthesis and degradation is fast, i.e., comparable to the redistribution processes
of the different receptor species. The reduced models are derived under the quasi-steady
state assumption that the receptor redistribution processes are much faster than the ligand
pharmacokinetics. This assumption is of the same type as the assumption underlying the
Michaelis- Menten model of enzyme reactions, where it is assumed that the complex formation,
dissociation and catalytic transformation are much faster than the transformation of substrate
into product. In order to finally derive reduced models, we have to make an additional
assumption on the time-scale of receptor synthesis and degradation. There are three different
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scenarios: receptor synthesis and degradation is (i) as fast as receptor redistribution (or
faster); (ii) slower than the time scale of ligand pharmacokinetics; or (iii) at an intermediate
time scale, i.e., comparable or faster than ligand PK but slower than receptor redistribution.
The first two scenarios correspond to our fast and slow scenario. Under these assumptions it is
possible to either treat receptor synthesis and degradation the same way as the redistribution
processes (in the fast scenario) or neglect it and treat the total amount of receptor as a
constant (in the slow scenario), since in the latter it would not impact the total number of
receptors on the time scale of interest.
Both scenarios will be used in the following to establish a link between the reduced and
the detailed model.
In the third scenario, however, receptor synthesis and degradation would need to be taken
into account in terms of an additional ODE. Unless further assumptions are made, this would
require to consider the full system of eqs. (2.3)-(2.7)—which is not suitable for PK parameter
estimation in clinical trials.
Reduced model of saturable distribution into the receptor system and linear
degradation (Model B)
The idea in deriving a reduced model of RME is to use the quasi-steady state assumption for
the receptor system (RS). This transforms the differential equations (2.4)-(2.7) into algebraic
equations for Rm, RLm, RLi, Ri. For a given number of extracellular ligand molecules Lex,
these algebraic equations can be solved explicitly. This allows us to compute the total number
of ligand molecules in the receptor system LRS = RLm +RLi as a function of the extracellular
number of ligands Lex. Based on LRS, the quasi-steady state number of intracellular ligand-
receptor complexes RLi can be computed, which determines the extent of elimination.
Model B describes the evolution of the total number of ligands Ltot = Lex + LRS in form
of the following ODE:
dLtot/dt = −kdegLRS with (2.8)
LRS =
BmaxLex
KM + Lex
(2.9)
Lex =
1
2
(
Ltot −Bmax −KM +√
(Ltot −Bmax −KM )2 + 4KMLtot
)
. (2.10)
The equations comprise three parameters: the maximal ligand binding capacity Bmax of the
receptor system (in units molecules), the number of extracellular ligand molecules correspond-
ing to a half-maximal binding capacity KM (in units molecules), and the degradation rate
kdeg (in units 1/time). In this reduced model the combination of saturable distribution and
linear degradation results in the overall saturable elimination of the ligand.
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For the two scenarios of slow or fast receptor synthesis and degradation, the functional
relation between the parameters Bmax, KM and kdeg and the parameters of the detailed
model of RME can be established. In the case of slow receptor synthesis and degradation, it
is
Bmax = R0 · kbreak + krecyRL + kinterRL
kbreak + kinterRL + krecyRL + kinterRL · kbreak/krecyR (2.11)
KM = KD ·
VγNA · kbreak
(
1 + kinterRLkoff +
krecyRL
kbreak
)
kbreak + kinterRL + krecyRL + kinterRL · kbreak/krecyR (2.12)
kdeg =
kbreak · kinterRL
kinterRL + kbreak + krecyRL
, (2.13)
where R0 is the total number of receptors and KD = koff/kon denotes the dissociation constant
of the ligand-receptor complex. In the case of fast receptor synthesis and degradation, the
relation between the parameters is
Bmax =
ksynth
kdegR
· krecyR · (krecyRL + klyso + kinterRL)
kinterRL · (klyso + krecyR · kdegRL/kdegR) (2.14)
KM = KD · VγNA · kinterR · (krecyRL + klyso + kinterRL · klyso/koff)
kinterRL · (klyso + krecyR · kdegRL/kdegR) (2.15)
kdeg =
klyso · kinterRL
kinterRL + klyso + krecyRL
, (2.16)
with klyso = kbreak + kdegRL.
Reduced model of saturable degradation (Model C)
The proposed Model C (see Fig. 2.4C) is a further reduction of Model B. It is based on
the additional assumption that the amount of ligand distributed into the receptor system is
negligible in comparison to the total amount of ligand molecules, i.e., Ltot = Lex +LRS ≈ Lex.
More formally, Model C can be derived from Model B under the assumption
Bmax
KM + Lex
 1, (2.17)
which implies LRS  1 and thus Ltot ≈ Lex from eq. (2.9). Substituting Lex by Ltot in
eq. (2.9) and LRS into eq. (2.8) yields the ODE for the total number of ligand molecules:
dLtot/dt = − VmaxLtot
KM + Ltot
. (2.18)
The model comprises two parameters: the maximal elimination rate of ligand molecules Vmax
(in units molecules/time) and the number of ligand molecules KM , at which the elimination
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rate is half-maximal. Exploiting the relation
Vmax = kdeg ·Bmax, (2.19)
we obtain the functional relations between Vmax and the parameters of the detailed model
of RME (Model A). In the case of slow receptor synthesis and degradation, the functional
relationship is given by
Vmax = R0 · kbreak · kinterRL
kbreak + kinterRL + krecyRL + kinterRL · kbreak/krecyR (2.20)
and KM is defined as in eq. (2.12). In the case of fast receptor synthesis and degradation, it
is
Vmax =
ksynth
kdegR
· klyso · krecyR
klyso + krecyR · kdegRL/kdegR (2.21)
and KM is defined as in eq. (2.15).
2.7 Integration of RME into compartmental PK models
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Figure 2.5: Two two-compartment models with linear clearance from the central compartment and
RME based on Model B (left) and Model C (right) in the peripheral compartment.
In order to facilitate the transfer of reduced models of RME into compartmental PK models
underlying PK data analysis and for use in the example of therapeutic protein receptor inter-
action, we explicitly state the system of ODEs for a two-compartment PK model. The model
comprises a central compartment (volume V1 (in units volume) and ligand concentration C1
(in units mass/volume)) from which linear elimination CLlin (in units volume/time) takes
place and a peripheral compartment (volume V2 and total ligand concentration C2), where
saturable elimination via receptor mediated endocytosis CLRS takes place (see Figure 2.5). In
19
2.7. INTEGRATION OF RME INTO COMPARTMENTAL PK MODELS
the peripheral compartment, we further distinguish between the concentration CRS within the
receptor system and the extracellular concentration Cex. The inter-compartmental transfer
flows are denoted by q12 and q21 (in units volume/time).
As in this Chapter we are interested in how to represent RME in PK models, the below
mentioned system of ODEs based on the reduced Models B and C represent the proposed
structural PK model that can be used for parameter estimation in PK data analysis of non-
clinical and clinical trials. The parameter values are determined by performing a fit of the
model to the specific in vivo data. Alternatively, the model might be used to scale-up in vitro
derived RME parameter values to the in vivo situation.
If Model B is used to describe the elimination by RME, the system of ODEs is
V1 · dC1/dt = q21 · Cex − q12 · C1 − CLlin · C1 + dosing (2.22)
V2 · dC2/dt = q12 · C1 − q21 · Cex − CLRS · CRS, with (2.23)
CRS =
Bmax · Cex
KM + Cex
(2.24)
Cex =
1
2
(
C2 −Bmax −KM +√
(C2 −Bmax −KM )2 + 4KMC2
)
, (2.25)
where dosing denotes a mass inflow (in units mass/time) of, e.g., an i.v. infusion over a given
time. The parameter Bmax denotes the total maximal ligand binding capacity in mass per
volume or mol per volume, KM denotes the concentration at which the binding capacity is
half-maximal, CLlin and CLRS denote the total elimination capacities (in units volume/time).
In terms of parameter estimation, the PK model contains eight parameters: V1, V2, q12, q21,
CLlin, CLRS, Bmax and KM , plus additional variables relating to dosing.
If Model C is used to describe the elimination by RME, the system of ODEs is
V1 · dC1/dt = q21 · C2 − q12 · C1 − CLlinC1 + dosing (2.26)
V2 · dC2/dt = q12 · C1 − q21 · C2 − Vmax · C2
KM + C2
, (2.27)
where Vmax denotes the total maximal elimination (in units mass/ time), and all remaining
parameters are defined as above. In terms of parameter estimation, the PK model contains
seven parameters: V1, V2, q12, q21, CLlin, Vmax and KM , in addition to the parameters relating
to dosing.
If the reduced models of RME are used as part of structural PK models to estimate pa-
rameters in the course of clinical data analysis, the question arises whether or not the identi-
fied RME parameters Bmax, KM , kdeg and Vmax allow for a mechanistic interpretation, e.g.,
whether Bmax can be interpreted as the maximal RME ligand binding capacity. This question
is tightly linked to the question of identifiability of model parameters, sometimes referred to
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as the inverse problem. Identifiability has been studied in detail in the context of compart-
mental models (see, e.g., [46, Chap. 5-9]). In general, the identifiability of model parameters
depends on the structural model (number of compartments, compartment to which the RME
process is linked, existence of additional routes of elimination etc.), prior knowledge of model
parameters and the quality of the experimental design [46, Chap. 5].
2.8 Protein distribution and elimination by RME
With respect to the pharmacokinetics of therapeutic proteins, two aspects of RME are of
particular importance:
1. distribution as a consequence of the drug binding to the receptor and subsequent inter-
nalization of the complex; and
2. elimination as a consequence of endocytosis.
Unfortunately both processes typically cannot be differentiated experimentally in pharma-
cokinetics. Model B explicitly takes into account the amount of drug LRS distributed in the
receptor system and the elimination by intracellular degradation, e.g., lysosomes. While the
elimination is a linear process in terms of LRS, the distribution into the receptor system itself
is a saturable process, specified in terms of Bmax and KM . Model C is derived from model
B by assuming in addition that LRS is negligible in comparison to the extracellular amount
Lex. In view of the above two sub-processes, this is equivalent to the assumption that the
distributional aspect of RME can be neglected. Notably, even if the distributional aspect
is negligible, the receptor system could still very efficiently transport ligand molecules into
the cell, where they are subsequently degraded. This can be explained from eq. (2.19). It
states that the maximal elimination rate Vmax is the product of the maximal ligand binding
capacity Bmax and the degradation rate constant kdeg. The maximal elimination rate Vmax
may still be large due to a large kdeg, even if Bmax is small. The latter implies a negligible
amount of ligand LRS within the receptor system. The receptor system acts as a mechanism
that transports ligand molecules into the cell to eventually degrade them. Whether or not
the receptor system also serves as a distribution phase is independent from the elimination
aspect. This yields the following guidance for the usage of the two reduced models:
Model B: Elimination and distribution of ligand into the receptor system are important
processes to be considered.
Model C: The distribution of ligand into the receptor system can be neglected, only the
elimination process is important, which in this case is non-linear.
Based on Model B and the computable criterion (2.17) it can easily be checked whether the
condition for the applicability of Model C are fulfilled. This will be demonstrated for the
EGF/EGFR system in Section 2.10 (see Figures. 2.6 and 2.7).
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The elimination process of RME is specified in terms of the parameters Vmax and KM .
Noteworthy, the maximal elimination rate Vmax is independent of the processes of complex
formation (kon) and dissociation (koff) of the receptor-ligand complex. However, the param-
eters kon and koff influence the amount of extracellular ligand molecules KM , at which the
elimination rate is half-maximal.
2.9 Nonlinear PK caused by RME
In this Section, we investigate the extent of nonlinearity in the context of the Michaelis-
Menten model defined in eqs. (2.26)-(2.27). We aim to examine the effect of drug and cell
properties on the nonlinearity of the pharmacokinetics, e.g., different drug affinities to the
receptor (different kon and koff values) or different rates of internalization and recycling of the
drug in different cells.
In the chosen setting of the two-compartment PK model (cf. eqs. (2.26)-(2.27)), the total
clearance CLtot is given by
CLtot = CLlin + CLRS = CLlin +
Vmax
KM + C
, (2.28)
where C denotes the relevant ligand concentration in the RME compartment (e.g., C2 in
eq. (2.27)). While the linear clearance is constant, the clearance attributed to RME varies be-
tween Vmax/KM for small ligand concentrations and 0 for high ligand concentrations. There-
fore, we consider the quotient Vmax/KM as a measure of the extent of nonlinearity, i.e., the
increase in total clearance for small ligand concentrations.
In order to jointly analyze the slow and the fast receptor synthesis and degradation scenario,
we set
R0 = Rm +Ri =
ksynth
kdegR
·
(
1 +
kinterR
krecyR
)
(2.29)
and replace the quotient ksynth/kdegR in eq. (2.21) by R0/(1 + kinterR/krecyR) according to
eq. (2.29). Moreover, we extend the definition of klyso to the slow scenario by setting klyso =
kbreak in this case (note: for the fast scenario klyso = kbreak + kdegRL). Then, the extent of
nonlinearity for both, the fast and the slow scenario, is given by
Vmax
KM
=
R0
VγNA
· kon
koff
kinterRL
(
1 +
krecyRL
klyso
)
+ 1
·
 1(
1 + kinterRkrecyR
)(
kinterR
krecyR
)
p, (2.30)
where p = 0 for the slow scenario and p = 1 for the fast scenario. The above equation allows
us to study in detail the influence of the various parameters on the extent of nonlinearity.
It can be inferred from Table 2.2 that ligand-specific, receptor system-specific as well as
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mixed parameters influence the extent of nonlinearity of the PK: nonlinearity increases for
higher affinity drugs (kon) and cell types, which have a higher receptor concentration at the
surface of the cell membrane (R0, krecyR) and faster degradation processes (klyso etc). In
contrast, higher values of koff , krecyRL and higher kinterR, kdegR will decrease the extent of
nonlinearity by resulting in a lower number of intracellular ligand receptor complexes, free
receptor molecules, or a smaller number of receptor molecules at the cell surface membrane.
Table 2.2: Contribution of the different parameters to the extent of nonlinearity. With increasing
value of the corresponding parameter the extent of nonlinearity will increase (N) or decrease (H). For
each parameter, it is indicated by RS or L whether it is related to the receptor system or the ligand,
respectively.
Parameter Nonlinearity RS or L
1 R0 N RS
2 krecyR N RS
3 kon N L
4 klyso N RS & L
5 kinterRL N RS & L
6 koff H L
7 kinterR H RS
8 krecyRL H RS & L
In order to more clearly highlight the contribution of the dissociation constant KD, we also
give the following alternative representation of eq. (2.30):
Vmax
KM
=
R0
VγNA
· 1
KD
· 1
1
kinterRL
(
1 +
krecyRL
klyso
)
+ 1koff
·
 1(
1 + kinterRkrecyR
)(
kinterR
krecyR
)
p . (2.31)
As can be inferred from the above relation, the extent of nonlinearity can be very different
for ligands with the same dissociation constant KD, but different absolute values of koff . The
difference depends on the relative magnitude of the two terms in the first denominator in
eq. (2.31), i.e., 1/koff to 1/kinterRL · (1 + krecyRL/klyso).
2.10 Case study: modelling zalutumumab (2F8) disposition
The analysis of drug-EGFR interaction are performed using data from the monoclonal anti-
body zalutumumab (2F8), as published by Lammerts van Bueren et al. [147]. Zalutumumab
is a human IgG1 EGFR antibody that potently inhibits tumor growth in xenograft mod-
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els and has shown encouraging antitumor results in a phase I/II clinical trial [13, 8]. We
transformed the originally published system of difference equations [147, Supplement] into
the corresponding continuous system of ordinary differential equations1 (ODEs):
d
dt
Apl = kipAint − kpiApl − kelApl (2.32)
d
dt
Aint = kpiApl − kipAint − kb
(
B̂max(Aint/Vint)
h
(Aint/Vint)h +KhM
−Ab
)
(2.33)
d
dt
Ab = kb
(
B̂max(Aint/Vint)
h
(Aint/Vint)h +KhM
−Ab
)
− k̂degAb, (2.34)
where Apl, Aint and Ab represent the amount of therapeutic protein in the plasma, interstitial
and binding compartment, respectively; Vint the interstitial volume, kpi and kip the rate con-
stants for transfer between the plasma and interstitial compartment, kb the rate constant for
binding to and dissociation from EGFR, and kel the elimination rate constant. Furthermore,
k̂deg denotes the rate constant for elimination by EGFR internalization and degradation,
B̂max the maximal binding capacity of the therapeutic protein to EGFR, KM the concen-
tration corresponding to B̂max/2, and h the Hill factor. The initial amount of drug Apl(0)
and the parameters are listed in Table 2.3. The reported value of KM = 0.5µ g/ml did not
allow us to reproduce the results in [147, Fig.1A]. Only a value of KM = 0.05µ g/ml exactly
reproduced the in silico data, hence we choose the corrected value for subsequent analyses.
Amounts are converted to concentrations by dividing by the corresponding volume.
Transforming the system of ODEs (2.32)-(2.34) from units [mg/kg] to [mg/ml] by dividing
by the corresponding volumes yields equations for Cpl = Apl/Vpl, Cint = Aint/Vint, Cb =
Ab/Vint, in terms of the following scaled parameters q12 = Vpl · kpi, q21 = Vint · kip, CLlin =
kel ·Vpl, Bmax = B̂max/Vint, CLRS = k̂deg ·Vint. The model (2.32)-(2.34) scaled to units [mg/ml]
can be directly compared to our PK model (2.22)-(2.25) with C1 = Cpl, Cex = Cint and
CRS = Cb, parameterized with the scaled parameters above. We remark that alternatively,
our compartmental PK models could have been stated in units [mg/kg].
Influence of receptor system properties on RME
We illustrate the approximation features of the two reduced models for predicting concentration-
time profiles of the ligand in comparison to the detailed model based on the EGF/EGFR
system. The initial concentration is Cex(0) = 40 nM. In Fig. 2.6 (left), the predictions of the
extracellular EGF concentration Cex is shown for the three Models A, B, & C. All models
result in very similar concentration-time profiles: Almost instantaneously, the amount of lig-
1The originally published equations in [147, Supplement] are identical to a certain discretization of the system
of ODEs (2.32)-(2.34). The advantage of stating the system as continuous ODEs is that subsequently any
numerical scheme can be used to solve them, in particular high accuracy ODE solver with adaptive step
size control.
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Table 2.3: Parameter values used by Lammerts van Bueren et al. [147]; KM has been corrected, see
text for details. Vpl represents the plasma volume.
Parameter Unit Value
1 kb h
−1 0.069
2 kpi h
−1 0.043
3 kip h
−1 0.043
4 kel h
−1 0.0055
5 Vint ml 70
6 Vpl ml 35
7 KM µg ·ml−1 0.05
8 B̂max mg · kg−1 2
9 k̂deg h
−1 0.005
10 Apl(0) mg · kg−1 2 and 20
11 h 1.0
and in the RS is in equilibrium. Due to the high concentration of ligand in comparison to
the concentration of receptor, the RS is saturated and the ligand is eliminated at a constant
rate. Between approximately 40-60 h, the system undergoes a transition from saturated to
non-saturated elimination, which is manifested in the linear decline in the final phase (in the
semi-logarithmic representation). For the EGF/EGFR system, the detailed model of RME
is well approximated by Model B and also by Model C, the latter taking into account only
the apparent saturable elimination. Based on the predictions of Model B, we computed the
amount of ligand LRS in the receptor system. In accordance with eq. (2.17), LRS is negligible
in comparison to the extracellular EGF concentration (cf. Fig 2.7, solid line).
In order to study the impact of LRS on the approximation quality of Model C, we artificially
decrease kdegRL by a factor of 10. All other parameters of the detailed Model A, including the
initial EGF concentration, are identical. Parameters of Model B and C have been recalculated
according to eqs. (2.14)-(2.16) and (2.21)+(2.15), respectively, resulting in particular in an
increased maximal binding capacity Bmax. The predictions of the concentration-time profile
of the extracellular EGF concentration Cex based on the three Models A, B & C are shown
in Fig. 2.6 (right). While Models A and B give almost identical results, the prediction based
on Model C differs significantly. Model C over-predicts the extent of elimination by RME. As
shown in Figure 2.7 the over-prediction corresponds to periods in time where the assumption
(2.17) is violated: While Bmax/(KM +Cex) is small for both settings up to time 60 h, it starts
to increase thereafter, in particular for the setting corresponding to Fig. 2.6 (right).
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Figure 2.6: Concentration-time profile of the extracellular ligand concentration for the Model A ( •◦ ),
Model B (  ) and Model C ( ♦ ). Left: Parameter values used according to Table 2.1. Right: As in
left Figure, but decreasing kdegRL 10 fold.
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Figure 2.7: Evolution of the ratio Bmax/(KM + Cex) for the two scenarios shown in Fig. 2.6 left
( ) and right ( ).
Influence of different cell types on RME
The detailed model A allows us to analyze the influence of processes on the overall disposition
of ligand in the extracellular space such as, e.g., the ligand receptor internalization rate
constant kinterRL. Alterations in kinterRL have been observed experimentally [154, 113] and
could be the result of a mutation of the EGF receptor. In view of eq. (2.30) we would expect
a decrease in the overall elimination capacity with decreasing internalization rate constant
kinterRL. Figure 2.8 (left) shows the impact of an altered kinterRL on the concentration-time
course of EGF with Cex(0) = 40 nM. As can be seen, cells with a reduced internalization
rate constant kinterRL/4 and kinterRL/16 show a much lower apparent elimination than the
reference cells with the rate constant kinterRL. The difference in the apparent elimination
does not only depend on the absolute magnitude of change of kinterRL, but more precisely on
the magnitude of change of 1/kinterRL · (1 + krecyRL/klyso) in relation to 1/koff , as can been
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inferred from eq. (2.31). Changes in kinterRL will have less impact, if 1/koff is large. This can
be seen in Figure 2.8 (right), which shows the same situation as in the left Figure, but with
koff decreased by a factor of 100 (we also decreased kon by the same factor in order to keep
KD constant).
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Figure 2.8: Illustration of the dependence of RME on the rate of internalization using the detailed
model of RME (Model A). Parameter values according to Table 2.1. Left: concentration-time profiles
of the extracellular ligand EGF (Lex) for three different internalization rate constants of the ligand–
receptor complex: kinterRL ( ), kinterRL/4 ( ), kinterRL/16 ( ). Right: same as before, but with
decreased association and dissociation rate constants: kon/100 and koff/100, respectively. Note that
KD is identical in the left and right graphics.
In Fig. 2.8, we studied the impact of different internalization rate constants kinterRL on
RME. An altered kinterRL could, e.g., result from a mutation in the EGF receptor, as it has
been observed experimentally [154]. Our analysis in Section 2.9 shows that the ligand elim-
ination rate is affected by various processes inside the cell. For example, the elimination
rate decreases with decreasing complex internalization rate constant, but the difference is
much less pronounced for a ligand with decreased association and dissociation rate constants
kon and koff—even though the dissociation constant KD is the same in both scenarios (see
Fig. 2.8, left vs. right). From the detailed Model A, this phenomenon is understandable: given
a ligand that forms a complex with rate constant kon, once the ligand-receptor complex is
formed at the membrane, its fate is a balance between dissociation (specified in terms of koff)
and internalization (specified in terms of kinterRL). If, e.g., koff/kinterRL  1 then the complex
will predominantely be internalized. Based on KD alone, this property of receptor systems
can not be observed. The ratio koff/kinterRL has recently been introduced as one of two key
parameters to characterize different cell surface receptor systems (termed the consumption
parameter) [133]. In general, our analysis shows that reduced ligand elimination from the
extracellular space can be due to altered processes inside the cell other than the velocity of
internalization of the complex. The influences of the processes can be deduced from eq. (2.30)
and is summarized in Table 2.2. The nonlinearity increases with parameters that accelerate’
the processes of receptor availability at the surface (R0, krecyR) or that accelerate’ the trans-
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port and intracellular degradation of extracellular ligand (kon, kinterRL, klyso). Counteracting
processes (related to the parameters koff , kinterR, krecyRL) decrease the extent of nonlinearity.
2.11 RME in the monoclonal antibody/EGFR system
In this Section we will illustrate how our unified theoretical approach to RME allows for
resolving seemingly contradictory statements about the performance of empirical models of
RME. In [147], Lammerts van Bueren et al. reported about a preclinical study involving a
mAb against EGFR in monkeys and their subsequent data analysis. They developed the
two-compartment pharmacokinetic model comprising a first-order elimination of the mAb
from plasma, a binding compartment (representing EGFR-expressing cells) that equilibrates
with the interstitial compartment, and a saturable internalization and degradation of bound
mAb. Lammerts van Bueren et al. concluded that the observed nonlinear decrease of mAb
concentrations in cynomolgus monkeys could not be explained by a saturable elimination in
terms of a Michaelis-Menten model and proposed an alternative model, which described the
data well. In a different study, the Michaelis- Menten model was reported to successfully
describe in vivo data for a monoclonal antibody [67].
The model proposed in [147] is comparable to the two-compartment model introduced in
the Section 2.7, eqs. (2.22)-(2.25). In order to understand the inferences made by Lammerts
van Bueren et al. [147], we simulated their model defined in eqs. (2.32)-(2.34) and compared
the results to the correspondingly parameterized Models B and C (see Fig 2.9, left). Since
the experimental data presented in [147] were not available and since model simulations and
data were reported to be in good agreement, we used the Lammerts van Bueren model as
a surrogate for the experimental data. As in [147], we choose a high and low initial mAb
input of 2 mg/kg and 20 mg/kg. While the predicted mAb plasma concentrations based on
Model B are identical to the prediction based on the Lammerts van Bueren et al. model,
predictions based on Model C deviate significantly. A closer inspection reveals that the
assumption Bmax/(KM +Cex(0)) 1 is violated for the low dose of 2 mg/kg. Consequently,
the amount of mAb inside the RS cannot be neglected and we would expect to see deviations
between predictions based on Model B and C. Hence, the use of a Michaelis- Menten based
nonlinear elimination in the interstitial compartment, which neglects the drug distributed into
the receptor system, leads to an over-prediction of drug elimination by RME (see Figure 2.9,
left).
The difference between the predictions based on Model B and C should disappear, if the
maximal binding capacity is sufficiently decreased. This is shown in Figure 2.9 (right), where
the binding capacity Bmax has been decreased to one 20th of its original value.
In summary, the inference made in [147] that a Michaelis- Menten term is not adequate
for modeling the nonlinearity present in the data is valid for the specific conditions of their
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experimental design. However, this cannot be generalized to a statement about the validity
of the Michael- Menten approximation of RME, as can be seen from Fig. 2.9 (right).
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Figure 2.9: Comparison of model predictions for zalutumumab (2F8) based on the Lammerts van
Bueren et al. model ( •◦ ) and the herein proposed compartment models (2.22)-(2.25) (  )and (2.26)-
(2.27) ( ♦ ). Left: parameterization as given in Table 2.3. Right: maximal receptor capacity Bmax
decreased to one 20th of the original capacity.
2.12 Summary of this chapter
Receptor mediated endocytosis plays a major role in the disposition of therapeutic protein
drugs in the body. It is suspected to be a major source of nonlinear pharmacokinetic behav-
ior observed in clinical pharmacokinetic data. So far, mostly empirical or semi-mechanistic
approaches have been used to represent RME [30, 77, 102, 67, 147, 35, 137, 135, 136]. A
thorough understanding of the impact of the properties of the drug and of the receptor sys-
tem on the resulting nonlinear disposition was still missing, as is how to best represent RME
in pharmacokinetic models. For example, a Michaelis-Menten based RME model as part of
a PK model allowed for describing data in one PK data analysis (e.g., [67]), it failed to do
so in another (e.g., [147]). Due to lack of a sound theoretical basis to understand the differ-
ent performances of empirical models, this certainly was an unsatisfactory situation. In this
Chapter, we presented a detailed mechanistic model of RME that explicitly takes into account
receptor binding and trafficking inside the cell and that is used to derive reduced models of
RME which retain a mechanistic interpretation. We find that RME can be described by an
extended Michaelis-Menten model that accounts for both the distribution and the elimina-
tion aspect of RME. If the amount of drug in the receptor system is negligible a standard
Michaelis-Menten model is capable of describing the elimination by RME. The herein pre-
sented analysis therefore gives a thorough background of RME and a clear rationale as to
when the proposed reduced models are applicable. Notably, a receptor system can efficiently
eliminate drug from the extracellular space even if the total number of receptors is small. We
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find that drug elimination by RME can result in substantial nonlinear pharmacokinetics. The
extent of nonlinearity is higher for drug/receptor systems with higher receptor availability at
the membrane, or faster internalization and degradation of extracellular drug.
The analysis of RME in this Chapter elucidates that cell-level target dynamics can have a
significant influence on the pharmacokinetics of the drug. By using the here defined functional
relations between the parameters of the detailed Model A and the reduced Models B and C
we will be able in the following Chapter 3 and 4 to use simpler models of the targeted receptor
system and interpret them as reduced models of RME with lumped parameters.
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3 The in vitro inhibitory effect of therapeutic
antibodies
In this Chapter, we will develop a mathematical framework for describing the effect of a
promising class of therapeutic proteins, therapeutic antibodies. In more detail, we develop
a receptor model which describes the action of the current therapeutic antibodies against
the EGFR and describes the time-dependent interactions of the drug, the ligand and the
receptor. We aim to develop a mechanistic model of the cell-level processes (as usually done
in systems biology) and study a transient drug concentration (as usually done in pharma-
cokinetic/pharmacodynamic modelling). We are interested in studying in silico the result of
modifying the antibodies’ biophysical properties and predicting the resulting inhibition of the
receptor system. In this Chapter we will study the system under conditions of a typical in
vitro experiment and in the closed microenvironment of a tumor cell in vivo. In the following
Chapter 4, the here developed cell-level model also will be used as the basis to couple the
pharmacokinetics of the drug with therapeutically relevant cellular processes and to study
the inhibition under general in vivo conditions.
The model focuses on receptor systems where the ligand and the receptor are internalized
by RME (which was discussed in chapter 2). RME is important for variety of receptor families
[4, 40, 57], including the therapeutically important receptor tyrosine kinase receptors which
are activated by growth factors and stimulate tumor growth.
In Chapter 2 we already developed a detailed model of RME (Model A) to derive structures
of reduced models. In this Chapter we are interested in making quantitative predictions and
therefore have to base our analysis on cell-level models which have been already validated and
for which experimentally determined parameter values are available in the literature. In the
first part of this Chapter we will present such current kinetic models of receptor activation
by ligand binding and receptor trafficking in the literature. Subsequently, we will build our
model by including the binding of the antibody to the receptor.
3.1 Mathematical models for receptor kinetics
As the basis of the following receptor trafficking models, consider the binding of a ligand L
to a receptor R, which forms a complex RL (Fig. 3.1)
Using the principles of mass action kinetics, changes in the number of receptor-ligand
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R
kon
koff
RLL+
ksynthR
Figure 3.1: The reversible binding of a ligand to the receptor results in a complex.
complexes RL can be described by Eq. 3.1.
d
dt
RL = kon ·R · L− koff ·RL. (3.1)
The association rate constant kon characterizes the velocity of the second-order interaction
between the receptor and the ligand, while the dissociation rate constant koff characterizes
the first-order dissociation of the complex.
The early mathematical models describing the activation of receptors on the cells’ surface
by polypeptide ligands were based on the well developed theory of enzyme kinetics. In this
setting, steady-state description of the dynamics of the system were developed [158]. Such
models allow to describe cell behavior and to measure parameters under more physiological
conditions. A basic model of receptor activation and trafficking based on mass action kinetics
was developed by Wiley et al. [158] and Gex-Fabry et al. [45]. The interactions between
the considered species are depicted in Fig. 3.2. A free receptor (R) and a free ligand ( L) can
R
kinterRLkon
koff
RL RLiL+
kdegR
ksynthR
Figure 3.2: A simple model of receptor activation. The binding of a ligand to the receptor results
in a complex which can be internalized by receptor mediated endocytosis. The receptor is subject to a
normal turnover described by the synthesis rate and its degradation rate constants.
reversibly form a complex on the surface of the cell (RL). This complex can be internalized
by forming an endosome (RLi). The internalized complex then can degraded by forming
a lysosome. The receptor is subject to a normal turnover, described by a synthesis rate
(ksynthR) and a degradation rate constant (kdegR). Interestingly, for many receptor systems
the endocytotic rate constant (kinterRL), which describes the velocity the complex is getting
internalized, is much higher than the normal internalization and degradation rate of the
unbound receptor (kdegR) [159]. This leads to a decrease in receptors at the cell surface in
presence of a ligand, a mechanism referred to as downregulation [3, 12, 64, 118, 134].
The developed kinetic and steady-state models of the receptor system were used to measure
the rate constants experimentally [159, 68, 86, 160] (a compressive description of the technics
can be found in [81]).
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An important feature of many receptor systems is the internalization of the receptor. Be-
cause receptors and ligands may also be internalized by the process termed endocytosis the
model was further extended by considering the internalization and recycling of the free and
bound receptor [16, 157] as depicted in Fig. 3.3. There is evidence that this dissociation and
R
kinterRLkon
koff
RL RLiL+
kdegR
ksynthR
Ri
kinterRkrecyR
krecyRL
kdegRL
Figure 3.3: A simple model of receptor activation. The binding of a ligand to the receptor results
in a complex which can be internalized by receptor mediated endocytosis. The receptor is subject to a
normal turnover described by the synthesis rate and its degradation rate constants.
the subsequent recycling of the receptor depends on the ligand bound to the receptor. For
example the epidermal growth factor (EGF) tends to remain bound to the epidermal growth
factor receptor (as described in Fig. 3.3) while transforming growth factor α dissociates from
the receptor in the endosome due to a changed pH value and the free receptor may be recycled
to the surface [139].
The receptor trafficking model can therefore be extended by the recycling of the free receptor
back to the surface (Fig. 3.4). The models discussed above describe the behavior of receptor
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Figure 3.4: A simple model of receptor activation. The binding of a ligand to the receptor results
in a complex which can be internalized by receptor mediated endocytosis. The receptor is subject to a
normal turnover described by the synthesis rate and its degradation rate constants.
systems sharing the common feature of receptor trafficking. They can therefore be used
to compare different receptor systems and characterize their behavior by defining specific
coefficient of the defined rate constants.
Shankaran et al. recently did this by building such a described generalized kinetic model
of receptor-ligand binding and internalization [133]. A given signaling or transport receptor
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system then represents a particular implementation of this canonical model with a specific
set of kinetic parameters. They identified two parameters, which can characterize the sys-
tems as avidity-controlled, consumption-controlled, or dual-controlled. Avidity characterizes
how efficiently a receptor system can capture extracellular ligand while the consumption is
the partition coefficient quantifying the probability that a captured ligand molecule will be
internalized before it dissociates from the receptor. For a receptor system as described in
Fig. 3.2 the avidity is defined as
γ =
konL
koffL
R∗
Na · Vcell
were R∗ denotes the steady-state number of molecules of free receptor at the surface at the
cell, Na denotes Avagadro’s number, and Vcell is the volume of extracellular medium per cell.
The partition coefficient defining the consumption of the system is defined as
β =
kinterRL
koffL
.
The idea presented by Shankaran et al. is that receptors might be sensitive to either one or
both coefficients if cellular changes (e.g., due to mutations or genome alterations) leading to
a change of the corresponding coefficient also result in a different response of the receptor
to the ligand. Changes affecting a coefficient, to which the receptor is not sensitive, will be
without consequence for the receptor response.
This sensitivity of the response to changes in the two coefficients can be used to define if
the system is
• avidity-controlled – changes in the efficiency of capturing extracellular ligands lead to
strong changes in the response to a changing ligand concentration
• consumption-controlled – changes in the probability that a captured ligand molecule
will be internalized before it dissociates from the receptor lead to strong changes in the
response to a changing ligand concentration
• dual-controlled – changes in both coefficients lead to strong changes in the response to
a changing ligand concentration
Interestingly they concluded that changes in the avidity modulates the behavior of the trans-
ferrin receptor and low-density lipoprotein receptor systems, whereas the consumption coef-
ficient has a high control over the function of the the vitellogenin receptor. The epidermal
growth receptor shows a dual-sensitivity to the coefficients.
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3.2 Our mathematical model for the inhibitory effect of
therapeutic antibodies
The following analysis of this Chapter is based on a cell-level model which we build by com-
bining the established receptor activation models described in Section 3.1 (Fig. 3.2) with a
kinetic model of the mechanism of action of anti-EGFR mAbs. While the drug-ligand inter-
action together with the experimentally derived parameter values have been inherited from
Fig. 3.2, the interaction with the antibody instead of the detailed description of the RME
processes used in Chapter 2 has been described by a simpler model. The model corresponds
to the mechanism of action of the anti-EGFR mAbs on the market or in clinical development
(Zalutumumab, Panitumumab, Cetuximab, IMC-11F8, and Nimotuzumab) [163]. In detail,
the reactions included in the model represent the binding of the drug to the receptor and
the formation of the drug-receptor complex. All the intracellular distribution processes are
lumped into a single net internalization rate of the drug-receptor complex. The extension of
the model therefore closely follows the discussed target-mediated drug-disposition models [87].
While the experimentally determined parameter values for receptor activation and traffick-
ing allow to make quantitative prediction, the processes of antibody internalization without
experimentally measured rate constants available have been lumped into one downregulation
rate. The influence of this downregulation rate on the inhibitory effect will be studied in this
Chapter. An important difference between TMDD and the here used submodel is that the
receptor dynamics in our model are described on a cell-level instead of the whole body scale.
This allows us to study the impact of specific alteration of cells on the inhibitory effect of
therapeutic antibodies. The developed model is depicted in Fig. 3.5. In the model, both lig-
L D
+
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koffD
kR kdegR
+
konL
koffL
kdegRL kdegRD
Cells’ functional responses
Initializes 
downstream 
signalling
RL R RD
kdegL
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Figure 3.5: The proposed model of receptor-ligand-drug interaction. The natural ligand and the drug
compete for the receptor binding.
and L and drug D are present in the extracellular space (with volume V ). The ligand enters
the extracellular space at rate kL, and is cleared with rate constant kdegL. The drug enters
the extra-cellular space at rate fdose(t). The free membrane receptor R is produced at rate
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kR and internalized with the rate constant kdegR. Both ligand and drug reversibly bind to
free receptors R with association rate constant konL and konD, respectively, and a dissociation
rate constant koffL and koffD, respectively. The resulting ligand-receptor complex RL and
drug-receptor complex RD are internalized by forming an endosome with the rate constant
kdegRL and kdegRD, respectively.
Based on the law of mass action, the rates of change for the molecular species are given by
the following system of ordinary differential equations (ODEs):
dL
dt
=
kL
V Na
− konL
V Na
R · L+ koffL
V Na
RL− kdegLL,
dD
dt
= fdose(t)− konD
V Na
R ·D + koffD
V Na
RD,
dR
dt
= kR − konLR · L− konCR ·D + koffLRL
+ koffDRD − kdegRR, (3.2)
dRL
dt
= konLR · L− koffLRL− kdegRLRL,
dRL
dt
= konDR ·D − koffDRD − kdegRDRD.
The species L and D are expressed in [M]; R, RL and RD are in units [# molecules]. Division
by the product of Avogadro’s constant Na and volume V ensures conversion from units [#
molecules] to [M]. The non-negative drug dosing rate is given by fdose(t) = f(t) · dose, with∫ ∞
0
f(t) dt = 1. (3.3)
Different dosing regimes can be modeled by choosing f(t) appropriately. Prior to any drug
administration, the system is assumed to be in steady state, resulting in some number of
active receptor RL = RL∗. The effect of the drug results from the inhibition of receptor
activation, i.e., from the change in the number of active receptor RL over time.
Parameters
For numerical simulations, we used experimentally determined parameter values [55, 115] for
the EGFR system. All receptor system parameters are listed in Tab. 3.1. The association rate
constant konD was set to be similar to the one of EGF while the dissociation rate constant
koffD was calculated by koffD/konD = KD accordingly to KD,drug as stated in Tab. 3.1, which
is the affinity of the drug zalutumumab for the EGFR[107]. For the beginning no downreg-
ulation was assumed to take place by the antibody (the internalization rate constant of the
drug-receptor complex kdegRD was set equal to the internalization rate constant of the free
receptor kdegR). Both, affinity and downregulation will be changed to investigate the optimal
biophysical properties of an anti-EGFR antibody.
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Table 3.1: Parameter values for the EGF receptor system. In the absence of ligand the cells were
set to have 2 · 105 cell surface receptors (R∗) corresponding to the EGFR level of human mammary
epithelial cells [133].
Parameter Unit Value
1 kdegR min
−1 0.02 [115]
2 R∗ 2 · 105 [133]
3 ksynthR min
−1 kdegR ·R∗
4 KD,ligand nM 2.47 [55]
5 koffL min
−1 0.24 [55]
6 konL nM
−1 ·min−1 koffL/KD,ligand
7 kdegRL min
−1 0.15 [115]
8 KD,drug nM 7 [107]
9 koffD min
−1 koffL
10 konD nM
−1 ·min−1 koffD/KD,drug
11 kdegRD min
−1 kdegR
For the in vitro situation (see Fig. 3.6) the drug is given as a bolus-dose of 10 µg/ml [48] at
time t = 0 which is represented by choosing f as a delta-distribution at t = 0. Also the ligand
concentration was 10 ng/ml [48] and assumed to be constant over the time of the experiment
by setting kL and kdegL much faster than the other processes. The volume of liquid in the
petri dish was set to 4 · 10−10 l/cell [133].
Ligand
Antibody
Target cells
Figure 3.6: In vitro conditions of cell culture experiments investigating the inhibition of EGFR sig-
nalling pathways by antagonistic mAbs
Inhibitory effect measures
One advantage of the cell-level PK/PD model is its ability to study the interaction of drug and
cell properties, like drug-receptor affinity, drug induced receptor internalization. Since we are
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investigating a transient inhibitory effect we consider the three following quantitative measures
of the response of the number of activated receptors over time (see Fig. 3.7). Following the
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Figure 3.7: The cellular model of receptor activation and inhibition links an extra-cellular drug con-
centration (right) to the inhibitory effect on receptor activation (left) and allows for studying three
different characteristics of the inhibitory effect: the integral, the peak, and the duration of inhibition.
administration of the drug the number of active receptors is decreasing because of the drugs
inhibitory effect on ligand binding. Subsequently, the drug concentration decreases either
because of the internalization of the drug bound to the targeted receptor or target independent
metabolization/excretion. Due to the production of receptor we assume that after the drug
disappeared, the receptor system goes back to its steady-state activation level from before
the treatment. This is the basis of the three transient measures of drug effect presented here
and the following mathematical derivation of the effect.
In the following we assume that after the drug The peak inhibition is defined as the minimum
number of active receptors relative to the steady state, that is,
peak =
RL∗ −min {RL(t)}
RL∗
, (3.4)
The duration of inhibition is the time it takes for the active receptors to recover back to 99%
of the steady-state level. The integral of inhibition is the area under the curve of the active
receptors with respect to their steady state, i.e.,
E =
∫ ∞
0
(RL∗ −RL(t)) dt. (3.5)
3.3 Translating biophysical properties into an inhibitory effect
The cellular model of the mechanism of action of therapeutic antibodies is used in the following
to predict the transient response of the receptor system to the presence of the drug in the
cells’ surrounding. The model generates a trajectory of the receptor species and the drug
concentration. This translates the biophysical properties of the drug into a transient change
in the number of activated receptors and therefore allows to tune these properties in silico
for the optimal perturbation of the receptor system of the target cell.
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Figure 3.8: Transient inhibition of receptor activation for the drug cetuximab. The number of active
receptors ( , right axis) is reduced by the drug ( , left axis). Due to the high affinity of the drug,
this inhibition happens immediately after administration of the drug. When the drug concentration is
reduced by to RME the activation of the receptor system recovers to the original steady-state.
As the first step we will investigate the transient inhibitory effect resulting from the drug
present in the surrounding of the cell. The system is set to be in steady-state when at
t=0 the drug is administered. As can be seen from Fig. 3.8 the number of active receptors
drops when the drug is competing with the natural ligand for the binding to the receptor.
At the same time the drug concentration decreases in the medium due to the binding to the
receptor and the subsequent internalization and degradation. This steady decrease of the drug
concentration leads to a recovery of the number of active receptors to the same steady-state
as prior to drug administration.
3.4 Impact of affinity and dose on inhibitory effect
As the next step, we studied the inhibitory effect of different drug affinities (KD) and doses
on the transient activation of the receptor (see Fig. 3.9). Our study reveals that a higher
drug-receptor affinity amplifies the peak inhibition and shortens the duration of inhibition
(see Figure 3.9, a). Higher doses of the inhibitor amplify both, the peak and the duration of
inhibition (Figure 3.9, b).
As can be seen from Fig. 3.10 (a), in vitro, the cumulative inhibitory effect does not depen-
dent on the affinity of the mAb to the receptor. Thus, we found that under the conditions of
a typical in vitro experiment (i) the cumulative inhibitory effect is the same for mAbs with
different affinities; (ii) the peak inhibition is amplified for antibodies with higher affinities and
(iii) the duration of inhibition is shorter for high affinity mAbs. In general, we found that
there is a trade-off between cumulative inhibition, peak inhibition and duration of inhibition:
39
3.5. IMPACT OF RECEPTOR DOWNREGULATION
0 50 100 150 200 2500
0.2
0.4
0.6
0.8
1
re
si
da
l a
ct
ive
 re
ce
pt
or
s
time[h]
0 500 1000 15000
0.2
0.4
0.6
0.8
1
re
si
du
al
 a
ct
ive
 re
ce
pt
or
s
time[h]
Figure 3.9: Transient inhibitory effect of a change in the drug properties. (a) Warmer color cor-
respond to higher affinities. The curve marked in ( ) corresponds to the affinity of zalutumumab.
The different affinities result in different shapes of the inhibition curves, with a higher peak inhibition
and a lower duration of inhibition for antibodies with high affinity. (b) Warmer colors correspond to
higher doses of the antibody which increase all three measurements of the inhibitory effect.
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Figure 3.10: Prediction of in vitro drug efficacy. (a) The cumulative inhibitory effect in vitro does
not dependent on the affinity (KD) but it does increase with the dose. (b) High affinity drugs show a
higher peak inhibition and a shorter duration of inhibition (c).
mAbs with higher affinity exhibit a higher peak inhibition, but this comes at the cost of a
shorter duration of inhibition, resulting in identical cumulative inhibitions. A higher cumu-
lative inhibitory effect can therefore only be achieved by increasing the dose but not by an
optimizing of the affinity of the drug.
3.5 Impact of receptor downregulation
Enforcing receptor downregulation by mAbs is argued to be an important part of the drug
inhibitory effect [96]. This analysis of the in vitro model shows that the cumulative inhibitory
effect is independent from the drug-receptor affinity and its downregulation potential. The
same dependency is found with respect to the downregulation potential. An increase of the
downregulation rate constant lead to a shorter duration of the inhibition and an amplified
peak inhibition as denoted in Fig. 3.11. The cumulative inhibitory effect is again invariant
for changes of the endocytic downregulation rate.
The downregulation of the receptor by the drug may allow the development of an antibody
with lower affinity as the current anti-EGFR antibodies, because a lower affinity together
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Figure 3.11: Transient inhibitory effect of different downregulation rate constants. Warmer color
correspond to higher downregulation rates. The blue curve represents a downregulation rate constant
of the drug-receptor complex which is equal to the rate constant of the free receptor.
with a higher downregulation results in very similar trajectories of the active receptor (see
Fig. 3.12).
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Figure 3.12: The relationship between downregulation and affinity. The response to zalutumumab is
marked in ( ). The transient response to an inhibitor with 5-fold lower affinity and higher downreg-
ulation than zalutumumab is shown in ( ) and ( ), respectively. The response to an inhibitor with
5 fold lower affinity and 5 fold higher downregulation rate constant is shown in ( ).
In conclusion the numerical solutions obtained with the experimentally obtained parameter
values for the EGFR system demonstrate that tuning drug parameters can shape the tran-
sient inhibitory response, but there is a trade-off between its duration and peak amplitude.
The integral of the inhibition can only be increased by increasing the dose and not by tuning
the biophysical properties of the antibody. Experimental results suggest that the affinity of
the antibody cannot determine their biological activity. Diaz Miqueli et al. [98] examined
the biological activities of three monoclonal antibodies (Ior egf/r3, Nimotuzumab, and Ce-
tuximab) in vitro and found no difference in their inhibitory effect despite different affinities
to the EGFR. Goldstein et al. [48] found also no differences between Cetuximab and a lower
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affinity variant anti-EGFR antibodies in vitro.
Our analyses suggests that the invariance of the inhibitory effect despite different affinities
may either be a consequence of the in silico determined invariance of the integral of inhibition
to changes in the affinity or the dose of the antibody was to high to see differences in the
peak inhibition due to the different antibody affinities.
3.6 Derivation of an exact formula for the inhibitory effect
The invariance of the inhibitory effect integral was demonstrated above by using parameter
values experimentally determined for the EGFR system. To prove that this is a inherent
feature of all receptor systems with such a structure and does not depend on the specific
parameter values we demonstrated that the exact formula for the inhibitory effect integral
can be derived. The derivation of the cumulative inhibitory effect is following the draft
“Receptor synthesis is the most important process for the cumulative effect of anti-EGFR
antibodies” by Krippendorff, Oyarzu´n & Huisinga [73]. The mathematical derivation of the
formula can be found in the Appendix 6.1. The relative inhibitory effect of an antagonistic
therapeutic antibody in the system of ODE’s denoted by Equations 3.2 is hence given by the
simple formula
Er =
dose
tendkR
. (3.6)
Since dose is the number of drug molecules given to the system and tend · kR corresponds to
the number of receptor molecules synthesized in the treatment period (see Appendix 6.1),
the ratio of these two numbers defines the percent inhibition of the receptor system during
the treatment. Following our theoretical analysis, by measuring only the synthesis rate of
the receptor, the dose needed for a desired percent inhibition of the receptor system can be
calculated.
3.7 Impact on cells with increased receptor levels
Upregulation of EGFR expression and aberrant activation of EGFR has been shown in many
human epithelial cancers, including those of the colon, lung, kidney, head and neck, breast,
prostate, brain and ovary [124, 105, 122, 149, 56, 142]. The extent of overexpression also
correlates with poorer clinical outcome [106, 95, 49]. Receptor levels as measured by im-
munohistochemical methods are therefore investigated as a potential predictor of response
to receptor inhibitors like mAbs [123, 128, 144]. The cell-level model (Eq. (3.2)) suggests
that elevated receptor levels of R∗ and RL∗ can be a consequence of not only an increased
receptor expression (increased ksynthR), but also of a reduced internalization of the receptor
(decreased kdegR and/or kdegRL). Alterations in cells influencing those rate constants are
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for example gene amplification, increased gene copy numbers, and mutations of the receptor
gene which influence receptor internalization. Reddy et al. [113] reports about such an alter-
ation of EFGR where a truncated cytoplasmic domain exhibits a decreased ligand-induced
internalization rate constant.
Following the developed kinetic model the steady-state total receptor number on the surface
of the cell can be calculated. The steady state of the receptor system is defined by[
− (kdegRL + koffL) konL
koff − (kdegR + konL)
][
RL
R
]
=
[
0
−ksynthR
]
(3.7)
and hence
R∗ = ksynthR · kdegRL + koffL
(kdegRL + koffL)(kdegR + konL ·  L)− koffL · konL ·  L (3.8)
RL∗ = ksynthR · konL ·  L
(kdegRL + koffL)(kdegR + konL ·  L)− koffL · konL ·  L . (3.9)
For analysing the inhibitory effect of a alteration of the rate constants ksynthR, kdegR, and
kdegRL we developed a cell model representing tumor cells with different alterations (Fig. 3.13).
We changed the rate constants of tumor cells to ksynthRc = ksynthR · α or kdegRc = kdegR · α
receptor
syntheses
receptor
internalization
receptor
syntheses
receptor
internalization
receptor
syntheses
receptor
internalization
a b c
Figure 3.13: Cells with different alterations of receptor trafficking we analysed for their response to
mAbs. In difference of (a) the normal cell the tumor cells have either a higher synthesis of the receptor
(b) or a decreased internalization of the receptor (c).
and kdegRLc = kdegRL · α, which corresponds to a α−fold alteration of receptor synthesis or
internalization of the free and bound receptor, respectively.
Using Eq. 3.9 it follows in the case of an alteration of the synthesis rate
RL∗,c
RL∗
=
ksynthRc
ksynthR
= α (3.10)
and hence the number of bound receptor is changed α−fold when the synthesis rate is changed
α-fold. In case the internalization rate of both, the free and the bound receptor is changed,
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the inhibitory effect on the receptor level is depending on the value of other rate constants:
RL∗,c
RL∗
=
1 + koffLkdegRL +
konL· L
kdegR
α2
(
1 + koffLkdegRL
)
+ konL· LkdegR
(3.11)
These alterations hence result in changes steady-state activation levels of the receptor system
and activate signalling pathways more strongly.
Figure 3.14 shows the transient inhibition time-curve for cells with different levels of the
receptor due to the two discussed alterations. In the case of a higher synthesis rate of the
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Figure 3.14: Transient inhibition dynamics for cells with overexpressed receptor proteins. (a) Marked
areas denote the cumulative inhibitory effect of the antibody. Warmer colors correspond to higher
synthese rates of the receptor, (b) and higher reductions in the internalization rate of the free and
activated receptor.
receptor the absolute cumulative inhibition is the same for all levels of receptor expression
(Figure 3.14, a). Since the same number of receptors on the tumor cell is inhibited over
time compared to cells with a normal expression, cells with increased expression are not more
susceptible to the treatment with mAbs than normal cells.
However, in the case of reduced internalization of the free or the activated receptor, the
cumulative inhibitory effect is increased (Fig. 3.14, b), which suggests that such cells are more
susceptible to the treatment than normal cells, in terms of the cumulative inhibition.
As shown above, a change in the biophysical properties of the antibody (like the affinity)
does not allow to change the cumulative inhibitory effect. Duration and peak inhibition
however can be changed. Fig. 3.15 shows the inhibitory effect of a change in the affinity
of the antibody on the duration of the inhibition and the peak inhibition. Cells with a
higher expression show the same relative peak inhibition as normal cells and a lower affinity
reduces this peak for the same amount (Fig. 3.15, a). Cells with a decreased internalization
demonstrate a shifted curve. Here an intermediate affinity of the antibody allows to optimize
the difference between the peak inhibition in normal and tumor cells. The duration in general
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increases for lower affinities (Fig. 3.15, b). Cells with a higher expression show the same
change of the duration in case of a modified affinity. An optimization of the affinity in terms
of a higher difference between normal and tumor cells is therefore not possible. Cells with
decreased inhibition show a longer inhibition than normal cells when a high affinity antibody
is used. If the affinity is decreased the duration of inhibition is longer in normal cells.
In conclusion, when aiming to optimize the difference between the inhibitory effect on tumor
and normal cells by adjusting the affinity a success depends on the nature of the alteration
and not at the number of receptors on the cells surface. This number is just a description of
the steady state while the alteration determine the dynamics of the system in the response
to a treatment with mAbs.
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Figure 3.15: Impact of a change in the affinity for the duration of inhibition and the peak of inhibition.
(a) The peak inhibition changes in a normal cell ( ) in the same way as in a cell with higher receptor
expression ( ) when changing the affinity of the antibody (KD). Cells with decreased internalization
of receptor ( ) have a shifted curve. (b) This is also the case for the duration of the inhibition.
A change of the affinity has the same result on normal cells and cells with a higher expression and
no optimization is therefore possible. Cells with decreased internalization show a different reaction to
changes in the affinity. For these cells a high affinity antibody maximized the difference between tumor
and normal cells.
3.8 Inhibition of receptor activation in the microenvironment of
tumor cells
In this Section we will study the inhibition of receptor activation in a microenvironment of a
tumor cell. For this we make the following assumption: In the close proximity of a tumor cell
the local ligand concentration is affected by RME. In the last sections we assumed the ligand
concentration to be constant and therefore unaffected by the inhibition of the receptor system.
Although in general this is a reasonable assumption, (e.g EGF concentration is usually tightly
controlled by other mechanisms) there exist situations, where the endocytic machinery acts
to regulate growth factors. For example in the development of Drosophila melanogaster local
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concentrations of growth factor in tissues are controlled by endocytosis [34]. The system of
ODE’s is described by the equations (3.2) with the ligand concentration changing according
to
dL
dt
=
kL
V Na
− konL
V Na
R · L+ koffL
V Na
RL− kdegLL. (3.12)
This is in contrast to the preceding in vitro situation, where we set kL and kdegL much
faster than the other processes and resulted effectively in a constant ligand concentration.
We will see that for the case that RME has an influence on the ligand concentration in
the microenvironment, therapeutic inhibition is counteracted by ligand accumulation. This
indicates that the processes and concentrations in a microenvironment of tumor cells may
not only have a crucial influence on the success of radiotherapy [151], but it also potentially
influences antibody based therapies. This Section follows closely [72].
Response to drug administration
Single bolus dose. In the following we consider the response of the receptor system to a
single bolus dose of the inhibitor. Figure 3.16 shows the time course of the drug concentration
in the microenvironment and the resulting number of active receptors RL for different values
of the ligand clearance rate kdegL. Following the bolus dose at time t = 0, the number of
activated receptors drops rapidly to a much lower level. Inhibition of active receptors is due to
the competition for free receptors between the natural ligand and the drug. Since binding to
receptor implies internalization and degradation, the drug concentration decreases over time
such that eventually the number of active receptors recovers to its unperturbed steady-state
level (dashed line).
Two phases in Fig. 3.16 can be identified: In a first phase the number of active receptors
decays below its steady-state level, resulting in an inhibition of the receptor system; in a second
phase, however, the active receptors are above their steady-state, resulting in an induction
of the receptor system. The extent of inhibition and induction depends on the clearance
kdegL. For kdegL = 0.01/min, the induction phase is almost absent, whereas for kdegL = 0
the induction phase is the highest. The inset in Fig. 3.16 shows the increase and decline
of the ligand concentration in the microenvironment of the cell. The ligand accumulation
is the consequence of the drug binding to the receptor resulting in less ligand bound and
degraded. For low values of kdegL, the extracellular ligand accumulates considerably, while
for high values of kdegL it is cleared by the receptor-independent route.
To further understand the relation between inhibition and induction, it is useful to quantify
the drugs’ inhibitory effect in a precise way. As a measure of the drugs’ inhibitory effect we
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Figure 3.16: Dynamic response of the number of active receptors (lines with •◦) and drug concentra-
tion (lines without marker) after bolus dose for different ligand clearance rates kdegL. Inset: Ligand
accumulation in the microenvironment of the cell over time.
define:
E =
∫ ∞
0
(
RL∗ −RL(t))dt. (3.13)
Thus, E measures the net inhibition as the sum of the inhibition and induction. Fig. 3.16
shows that small values of kdegL increase the induction phase and decrease the inhibition
phase, implying a lower net inhibition according to eq. (3.13). Moreover, in the case of
kdegL = 0 we numerically observe a zero net inhibition (E = 0), which suggests that ligand
accumulation totally counteracts the drugs’ inhibitory effect.
Multiple bolus dose. A dosing strategy to prevent the induction phase, could be to ad-
minister a follow-up dose before the induction phase starts. As can be inferred from Fig. 3.17,
this first prevents the induction, but comes with the cost of a larger induction phase after
the final dose. This is due to a longer ligand accumulation phase (see inset in Fig. 3.17). For
kdegL = 0, numerical computations show a zero net inhibition as in the previous case.
Theoretical analysis of net inhibition
In the following we analytically show that in the limiting case when kdegL = 0, the net
inhibition vanishes and this impact is independent of the parameter values. Therefore, in this
scenario the extent of ligand accumulation and the resulting induction phase do not depend on
the model parameters, which suggests that it is a structural property of the studied receptor
system.
It is convenient to express eqs. (3.2) in terms of the deviations of the species from their
47
3.8. INHIBITION OF RECEPTOR ACTIVATION IN THE MICROENVIRONMENT OF TUMOR CELLS
0 100 200 300 400 50010
0
101
102
D
[n
M
]
time[h]
102
103
104
R
L
[m
o
le
c
u
le
s]
0 5000
10
20
L
[n
M
]
Figure 3.17: Dynamic response of the number of activated receptors (lines with •◦) and drug concen-
tration (lines without marker) after multiple bolus doses for kdegL = 0. Inset: Ligand accumulation in
the microenvironment of the cell over time.
steady-state values. We define these incremental variables as
L¯(t) = L∗ − L(t), R¯D = RD∗ −RD(t),
R¯(t) = R∗ −R(t), R¯L = RL∗ −RL(t),
D¯(t) = D∗ −D(t).
The resulting system of ODEs in terms of
x¯(t) =
[
L¯(t) D¯(t) R¯(t) R¯L(t) R¯D(t)
]T
is then given by
d x¯
dt
= Ax¯(t) +BRLR¯(t)L¯(t) +BRDR¯(t)D¯(t)−Bf(t), (3.14)
with x¯(0) =
[
0 −D(0) 0 0 0
]T
, and where A is the Jacobian of the right hand side of
(3.2) evaluated at the steady state (given in eq. (3.15)). The vectors BRL, BRD and B are
given by
BRL =
[
konL
V Na
0 konL −konL 0
]T
,
BRD =
[
0 konDV Na konD 0 −konD
]T
,
B =
[
0 1 0 0 0
]T
.
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A =

−konLR∗V Na 0 −
konLL
∗
V Na
koffL
V Na
0
0 −konDR∗V Na − kdegD 0 0
koffD
V Na
−konLR∗ −konDR∗ −konLL∗ − kdegR koffL koffD
konLR
∗ 0 konLL∗ −koffL − kdegRL 0
0 konDR
∗ 0 0 −koffD − kdegRD
 .
(3.15)
Integration of (3.14) from t = 0 to infinity gives
x¯(∞)− x¯(0) = A
∫ ∞
0
x¯(t) dt+BRL
∫ ∞
0
R¯(t)L¯(t) dt
+BRD
∫ ∞
0
R¯(t)D¯(t) dt−B
∫ ∞
0
f(t) dt. (3.16)
Under the biologically reasonable assumption that when the drug disappears the receptor
system goes back to its old steady-state activation level (described in Section 3.2), the stability
of the system implies that x¯(∞) = 0, and using the initial condition yields∫ ∞
0
x¯(t) dt = A−1B ·Dose
−A−1BRL
∫ ∞
0
R¯(t)L¯(t) dt
−A−1BRD
∫ ∞
0
R¯(t)D¯(t) dt. (3.17)
We notice that E =
∫∞
0 [x¯(t)]4 dt and moreover,[
A−1B
]
4
=
[
A−1BRL
]
4
=
[
A−1BRD
]
4
= 0, (3.18)
which finally implies E = 0. Hence, in absence of receptor-independent ligand clearance, the
inhibition and subsequent induction phase are identical, resulting in a zero net inhibition.
Since this phenomenon is independent of any drug- and receptor- specific parameters, it is
suggested that it is a structural feature of the considered receptor class.
3.9 Summary of this chapter
In this Chapter, we extended a systems biology model of receptor activation by the mechanism
of action of mAbs (section 3.2). This allowed us to study the impact of changed biophysical
properties of mAbs on the inhibitory effect (section 3.4 and 3.5).
We numerically studied large perturbation of the system and translated this transient effect
of the antibody into three different measures of inhibitory effect. We further derived an exact
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formula for the effect of mAbs in vitro (Eq. (6.17)), which has two advantages: (i) It describes
the exact effect following big perturbations of the network and (ii) needs only a subset of the
parameter values. Our theoretical analysis identifies only one parameter value of the cell-level
model which is important for the inhibitory effect, the synthesis rate of the receptor.
Another advantage of building a kinetic model of the EGFR is the ability to include cell
alteration found in tumor cells (section 3.7). We demonstrated that when tumor cells are
characterized by their number of receptor at the cell surface using immunohistochemistry,
this only describes a steady state of the system. More interesting for the response to a
treatment with mAbs is their dynamic response and this can be remarkably different for
different cell alterations, although the cells might present similar numbers of receptors on the
surface. A tumor cell with a higher expression of the receptor is harder to inhibit with mAbs
due to the change of the before identified most important parameter of the system, ksynthR.
Tumor cells with decreased internalisation of the receptor show a stronger response to mAbs
and, in contrast to cells with a higher expression, may allow to optimize the antibody for a
stronger selectivity for tumor cells.
The inhibitory effect of antibody-based therapeutics for targeting tumors is therefore influ-
enced by cell-level kinetic processes. In the last part of this Chapter (section 3.8) we identified
another kinetic mechanism with the potential to compromise the inhibitory effect, namely the
accumulation of ligands in the microenvironment of tumor cells. Receptor trafficking can have
a critical influence on the ligand concentration in the cells’ environment as was shown for the
EGF-EGFR system in vitro [113]. We therefore analyzed the inhibitory effect of inhibiting
such a receptor system, and found that the response of the receptor system to the drug in
this case can have two counteracting phases: An initial inhibitory phase and a second in-
ductive phase. The latter is due to extracellular accumulation of the ligand, which is larger
for environments where receptor-independent ligand clearance is slow. In such situations the
inhibitor only postpones the activation, until the local concentration of the drug has suffi-
ciently declined, acting as a memory of the prevented activation. In the limiting (theoretical)
case when there is no receptor-independent ligand clearance, the induction of active receptors
totally offsets the inhibitory response and renders a nil total inhibitory effect. The dosing
function can be regarded as an external input signal that is applied to the receptor system
to control its activation. The phenomenon of counteracting ligand accumulation constitutes
a “fundamental limitation” in the inhibition of the receptor system, which is independent of
the parameter values and resembles those that typically arise in Control Engineering [132].
The study of fundamental limitations is an extensive field of research [41] that addresses the
question how the structure of the system limits certain characteristics of every possible re-
sponse to a class of inputs. Our analysis suggests that this kind of limitations can also play
a role for antibody based cancer treatment.
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4 The in vivo effect of therapeutic antibodies
As shown in the preceding chapters, the identification of targets for protein drugs against
complex diseases benefits today from the availability of systems biology models of therapeu-
tically relevant cellular processes. One practical example is the successful development of
MM-121, a previously unidentified anticancer therapeutic designed using a systems approach
[130]. So far, such information about the dynamics of the targeted system is neglected in
later stages of the drug development process when pharmacokinetic modeling is used to guide
dose finding and analyze preclinical or clinical in vivo data. As shown in Chapter 2, this is
especially critical for therapeutic proteins, where drug effect and pharmacokinetics are in-
herently interdependent. In this Chapter, by integrating cell-level models with established
pharmacokinetic models, we translate biophysical properties of protein drugs into a transient
drug effect in vivo. As before, we illustrate the approach for anti-EGFR antibodies in cancer
therapy. Here we combine in vitro determined parameters (as used in Chapter 3) with phar-
macokinetic data from cynomolgus monkeys (as used in Chapter 2). The primary objective
of this Chapter is to develop a strategy to integrate cell-level kinetic models into systemic
pharmacokinetics models and secondary to translate biophysical properties of protein drugs
into in vivo efficacy. We combine the traditional modeling approaches of systems biology and
pharmacokinetics while importantly retaining the single-cell as the fundamental unit of the
model.
4.1 Our model of the inhibitory effect of therapeutic proteins
The pharmacokinetic part of the model is represented by a two-compartment model as used
in chapter 2 and described in section 2.2. For the cell-level submodel we use a description
of RME whose complexity lies between the very detailed description of the model used in
Chapter 2 and the reduced model used in Chapter 3 corresponding to the TMDD description
of antibody disposition. As before, due to the lack of experimentally determined parameters
for the antibody, we lumped the distribution of the antibody inside the cell into one internal-
ization rate (as described in Chapter 3). In contrast to the model in Chapter 3, we explicitly
considered the internalization and recycling of the free receptor (which was part of the de-
tailed model). Only this allowed us to accurately describe the measured plasma concentration
of zalutumumab in cynomolgus monkeys (see section 4.2). A rationale for this change of the
model is given in the discussion in Chapter 5
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The developed cell-level PK/PD model is shown in Fig. 4.1(b) and (c). Based on the law of
mass action, the rates of change for the molecular species are given by the following system
of ordinary differential equations (ODEs):
Compartment model:
Vc
dDc
dt
= −qcpDc + qpcDp − CLlinD ·Dc,
Vp
dDp
dt
= +qcpDc − qpcDp
+Nh · koffD · SF ·RD −Nh · konD · SF ·R ·Dp
+Nt · koffD · SF ·RDt −Nt · konD · SF ·Rt ·Dp,
(4.1)
Normal cells:
dR
dt
= kRh − konLR · L− konDR ·Dp
+ koffLRL+ koffDRD − kdegR ·R+ krecyR ·Ri,
dRi
dt
= kdegR ·R− krecyR ·Ri − kexit ·Ri,
dRL
dt
= konLR · L− koffLRL− kdegRLRL,
dRD
dt
= konD ·R ·Dp − koffDRD − kdegRD ·RD,
(4.2)
Tumor cells:
dRt
dt
= kRt − konLRt · L− konDRt ·Dp
+ koffLRLt + koffDRDt − kdegR ·Rt + krecyR ·Rit,
dRit
dt
= kdegR ·Rt − krecyR ·Rit − kexit ·Rit,
dRLt
dt
= konLRt · L− koffLRLt − kdegRLRLt,
dRDt
dt
= konD ·Rt ·Dp − koffDRDt − kdegRD ·RDt.
(4.3)
The model describes two compartments with volumes of Vc and Vp. The drug is present
in concentrations Dc and Dp, respectively. The parameters qcp and qpc denote the transport
rate constants from the central compartment to the peripheral, and vice versa. The drug is
cleared from the central compartment with rate constant CLlinD. The drug in the peripheral
compartment interacts with the receptors of normal cells (Fig. 4.1 a), or normal and tumor
cells simultaneously (Fig. 4.1 b), expressed by equations (4.2) and (4.3). R, Ri, RL, and
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Figure 4.1: Schematic illustration of the cell-level pharmacokinetic/pharmacodynamic model for an-
alyzing the inhibitory effect on receptor activation of anti-EGFR antibodies. (a) Cell-level receptor
model of receptor activation and inhibition. The cellular model describes the transient inhibitory effect
of a therapeutic antibody (D) on the formation of active ligand(L)-receptor complexes (RL) through
the binding to the free receptor (R) and the formation of a antibody-receptor complex (RD). Left:
We studied three different transient measures of the reduction in the number of active receptors: the
integral, the peak, and the duration of inhibition. Right: The receptor dynamics, at the same time,
effect the antibody concentration in the body, since the binding of the drug constitutes a target-mediated
clearance mechanism. (b) Cell-level pharmacokinetic/pharmacodynamic model. The model describes
the observed pharmacokinetics of therapeutic antibodies and includes a target independent linear clear-
ance mechanism (CLlinD) from the central compartment and an exchange of drug described by the flux
(qpc and qcp). The central and the peripheral compartments have a volume of Vc and Vp, respectively.
The cell-level model depicted in (a) is integrated in the peripheral compartment. This cell-level phar-
macokinetic model is used to study the trajectory of the drug concentration and the optimal biophysical
properties of anti-EGFR antibodies. (c) Extended cell-level pharmacokinetic/pharmacodynamic model
including tumor cells with elevated EGFR levels due to different alteration of receptor dynamics. The
extended cell-level pharmacokinetic model is used to compare the inhibitory effect of therapeutic anti-
bodies on tumor cells and normal cells to optimize tumor specificity.
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RD are the numbers of free receptors, free internalized receptors, ligand–receptor complexes,
and drug–receptor complexes per normal cell, respectively. Similarly, Rt, Rit, RLt, and RDt
denote the respective numbers in the tumor cells.
Both ligand (L) and drug (Dp) reversibly bind to the free receptors with association rate
constants konL and konD, and dissociate with rate constants koffL and koffD. The free membrane
receptors are internalized with rate constant kdegR and recycled with rate constant krecyR or
degraded with rate constant kexit. The drug–receptor complex and ligand–receptor complex
are internalized with rate constant kdegRD and kdegRL, respectively. All molecular species are
in number of molecules per cell, except L, Dc and Dp which are in mg/ml. In equation (4.1),
the factor SF = MW ·10
3
Na
ensures conversion from units number of molecules to mg.
For numerical simulations, we used the parameter values given in Table 4.1 and 4.2. The
comparison of the different therapeutic antibodies against the EGFR are based on the affinity
values stated in Table 4.3.
Table 4.1: Parameter values for the EGF receptor system. NCalculated in Section 4.2
Parameter Unit Value
1 konL M
−1 · s−1 2.9 · 106 [68]
2 koffL h
−1 0.24 [68]
3 kdegR h
−1 0.0172 [68]
4 kdegRL h
−1 0.8460 [68]
5 kRh cell
−1 · h−1 1.3824 · 104 [68]
6 krecyR h
−1 3.4800 [140]
7 kexit h
−1 0.1320 [140]
8 konD M
−1 · s−1 konL
9 kdegRD h
−1 0.005 [147]
10 Nh 2.9434 · 1010 N
11 MWmAbs dalton 148000
The parameter konD in units
1
mg
ml
·h is converted from the traditionally used konD in units
1
nM ·h by multiplying with
1
10−9·MWmAbs . It was assumed that concentration of all EGFR
ligands is five times the concentration of EGF, L = 5 · 0.35 ng/ml [15].
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Table 4.2: Pharmacokinetic parameters determined in vivo by [147].
Parameter Unit Value
1 kb h
−1 0.067 [147]
2 kpi h
−1 0.043 [147]
3 kip h
−1 0.043 [147]
4 kel h
−1 0.0055 [147]
5 Vi ml 70 [147]
6 Vp ml 35 [147]
7 KM mg ·ml−1 0.5 · 10−3 [147]
8 Bmax mg · h−1 2 [147]
9 CLlinD ml · h−1 kel · Vp
Table 4.3: Affinities and Isotypes of the considered therapeutic antibodies against the EGFR. Values
taken from [107].
Antibody Affinity (M) Isotype
1 Panitumumab 5 · 10−11 IgG2
2 Cetuximab 4 · 10−10 IgG1
3 IMC-11F8 3 · 10−10 IgG1
4 Nimotuzumab 1 · 10−9 IgG1
5 Zalutumumab 7 · 10−9 IgG1
4.2 Integrating in vitro determined cell-level receptor dynamics
into whole-body pharmacokinetic models
To analyze preclinical or clinical pharmacokinetic data of protein drugs, empirical compart-
mental models (see Chapter 2 and described in section 2.2) have been typically used[30, 77,
102, 67, 147].
In these models, the interaction of the drug with its target is represented by an empirical
or semi-mechanistic term, accounting for the saturable degradation capacity of the target
system.
Our approach of integrating cell-level kinetics into systemic pharmacokinetic models is a
two step process: Starting with the compartment model, we first replace the empirical or
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semi-mechanistic term with a kinetic model at the single cell level, and then secondly scale
the effect of this cellular level on the pharmacokinetics with the number of relevant cells. We
define relevant cells as those cells expressing the target and coming in contact with the drug.
Below, we illustrate the construction of such a cell-level pharmacokinetic model for the in
vivo effect of the antibody zalutumumab.
Zalutumumab (2F8) is an IgG1 antibody against EGFR that potently inhibits tumor growth
in xenograft models and has shown promising results in phase I/II clinical trials[13, 8]. Lam-
merts van Bueren et al.[147] have developed an empirical pharmacokinetic model of zalu-
tumumab in cynomolgus monkeys which accurately describes experimental plasma data for
high and low doses (Chapter 2). The model does however not allow the in vivo inhibitory
effect of zalutumumab to be predicted. Hence, the impact of the biophysical properties of the
drug on its effect can not be addressed using such a model.
In the empirical model, the interaction of zalutumumab with its target is represented by
an Michaelis-Menten term representing the saturable drug-receptor binding and subsequent
degradation. This term is the key to link pharmacokinetics and target dynamics, since (as
demonstrated in Chapter 2) it represents the degradation capacity of the relevant cells. To
describe the cell-level kinetics we use a canonical model of ligand-receptor activation and
trafficking[133, 68, 140] which is parameterized using rate constants that have been experi-
mentally determined in human fibroblast cells[68, 140] (Fig. 4.1, a). The number of relevant
cells was then estimated by comparing the degradation capacities of all relevant cells to the
degradation capacity of the single-cell model, which was determined by model reduction:
In quasi-steady state the number of drug-receptor complexes is given by:
RD∗ =
kRh
kdegRD
·Dp
kdegRD+koffD
kdegRD·konD · (
kexitkdegR
kexit+krecyR
+ L · konL·kdegRLkoffL+kdegRL ) +Dp
. (4.4)
The maximal binding capacity of the cell level model is therefore described by
Bmax,cell =
kRh
kdegRD
. (4.5)
The number of relevant cells can be estimated by comparing the maximal in vivo binding
capacity to the in vitro binding capacity of a single cell
Nh =
Bmax
SF ·Bmax,cell =
Bmax · kdegRD
SF · kRh , (4.6)
where SF ensures scaling of units.
This finally allowed us to replace the empirical term in the compartment model by the
scaled kinetic model of a single target cell (see Fig. 4.1, b and Section 4.1).
Importantly, our approach does not involve the refitting of parameters; all parameter values
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are either inherited from the original compartment model or have been determined in vitro.
The proposed approach to build cell-level pharmacokinetic models is applicable to various
therapeutic proteins where the target dynamic has an definable impact on the pharmacoki-
netics.
To assess the integration of the single cell kinetic model and how it feeds back on the
pharmacokinetics, we compared our model with the original empirical compartment model.
The predicted time-courses of the drug concentration showed good agreement for both, a
high 20 mg and low 2 mg dose (Fig. 4.2(a)). At the same time, the cell-level pharmacokinetic
model was used to predict the dynamics of the receptor system upon drug administration
(Fig. 4.2(b)). Our model correctly predicted that the saturation in monkey tissue which
expresses normal receptor levels was established at doses between 2 and 20 mg/kg[147] (see
Fig. 4.2(b), inset).
The cell-level pharmacokinetic/pharmacodynamic model then was used to predict the num-
ber of activated receptors over the duration of the treatment, which is in vivo difficult to
examine. Our model predicted that the low dose (2 mg) of antibody reduces the number of
active receptors by about 35%. It is then followed by a recovery period secondary to a slow
reduction of drug concentration (Fig. 4.2(b)). On the other hand, the higher dose (20 mg)
almost completely inhibited receptor activation for a period of around 20 days. The start of
the recovery period coincided with the transition from saturated to linear pharmacokinetics
between days 20 and 25. Thus, the model suggests that changes in pharmacokinetics might
act as a biomarker for changes in the inhibitory response. Further, we have compared re-
ceptor drug saturation with the inhibition of receptor activation. Both only corresponded
initially, while at later points in time the receptor saturation underestimated the inhibitory
effect of the antibody. This highlights the importance of adopting an integrated kinetic model
to translate the binding of the drug into its actual inhibitory effect on receptor activation.
The model only allowed to reproduce the zalutumumab time-curve when an internalized
free receptor was included in the model which can be recycled to the surface. For models
which lack such a pool of receptor, there was a poor agreement between our model and the
zalutumumab time-curve.
4.3 Optimizing drug characteristics
One important advantage of the cell-level pharmacokinetic/ pharmacodynamic model is its
ability to study the impact of drug properties such as the dose, drug-receptor affinity, and
drug induced receptor internalization on the inhibitory response under in vivo conditions.
Since we investigated a transient inhibitory effect we again consider the three quantitative
measures of the response defined in section 3.2(see also Fig. 4.1(a)):
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Figure 4.2: Pharmacokinetics of zalutumumab in cynomolgus monkeys and prediction of the inhibitory
effect on a cellular level using the model depicted in Fig.4.1(b). (a) Predictions of zalutumumab in the
central compartment ( ) and the peripheral compartment ( ) for a high dose of 20 mg and a low
dose of 2 mg by the cell-level pharmacokinetic model. The model predictions are in good agreement with
the empirical pharmacokinetic model of Lammerts van Bueren[147] ( and ). The experimentally
validated profiles from Lammerts van Bueren are marked with a ♦. (b) Predictions of the residual
EGFR activation per cell based on the cell-level pharmacokinetic model (Fig. 4.1 (b)) for the high
dose ( ) and the low dose ( ). The inset depicts the corresponding relative number of drug-bound
receptors at the membrane. This predicted saturation corresponds for both doses with the experimentally
measured receptor saturation in Lammerts van Bueren[147].
Affinity and dose.
We studied the inhibitory effect for a range of affinities, including those of anti-EGFR mAbs on
the market or in clinical development: zalutumumab, panitumumab, cetuximab, IMC-11F8,
and nimotuzumab. All these antibodies act antagonistically [163]. Our analysis focused on
optimizing the direct inhibitory effect, i.e., reducing the number of activated receptors at
the cell membrane. Since all the analyzed antibodies are either IgG1 or IgG2, their target-
independent clearance was assumed to be identical [99]. The percentage of active receptors
over time is shown in Figure 4.3(a). Despite 20-fold differences in target affinities (see Table
4.3 in Supplement), the transient inhibition pattern were similar. As seen in Figure 4.3(b)-
(d), this phenomenon is a consequence of an effect plateau in the inhibitory responses. For
high affinity drugs located in the plateau range, an increased affinity does not translate into
a stronger inhibition. For the integral effect our theoretical analysis (Appendix 6.2) suggests
that this a structural feature of the system that does not depend on specific parameter values.
Shankaran et al. [133] identified the ratio between the dissociation and downregulation rate
constants (kdegRD/koffD, termed the “consumption parameter”) as a key parameter to char-
acterize cell surface receptor systems. As discussed in section 3.1, it quantifies the likelihood
that a drug is internalized rather than dissociated upon binding the receptor. We found that
this is also an important parameter for antagonistic mAbs, since those with a high consump-
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Figure 4.3: Inhibitory effect of different antibodies using the cell-level pharmacoki-
netic/pharmacodynamic model shown in Fig.4.1(b). (a) Predicted transient inhibitory effects
of five antibodies on the market or in clinical development with different affinities (see Table 4.3) for
a 20 mg dose ( ) and a 2 mg dose ( ). The different mAbs show a similar transient inhibitory
effect despite their affinities vary 20-fold. (b)-(d) Inhibitory effect resulting from different affinities
(KD = 1/affinity = koffD/konD) and downregulation rates (kdegRD). The antibody is quantified by the
three different measures defined in Fig.4.1(a): (b) the integral of inhibition, (c) the peak inhibition,
and (d) the duration of inhibition, for the 20 mg dose ( ) and 2 mg ( ) dose. The shaded area
indicate the affinity range of the five considered anti-EGFR antibodies on the market or in late stages
of the development. The different affinities were realized in silico by altering the dissociation rate
constant koffD, while the association rate constant was kept constant. For low affinity drugs, the
inhibitory effects can be increase by increasing the affinity to the target. For high affinity drugs (such
as those in the shaded area), the existence of a plateau region does not allow for further optimization
of the direct inhibitory effect.
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tion parameter are located on the effect plateau and their direct inhibitory effect could not be
further increased (Appendix 6.2). For lower affinity drugs the target independent clearance
is more dominant such that RME (and therefore drug effect), decreases for lower affinity.
Receptor downregulation.
Enforcing receptor downregulation by mAbs is argued to be an important part of the drugs’
effect[96]. For anti-EGFR antibodies, we found that endocytic downregulation only con-
tributes to a negligible extent to the direct inhibitory effect of high-affinity antibodies (Fig. 4.3(b)-
(d)) on the market or in late development. For medium affinity antibodies, however, an
increased downregulation could increase the direct inhibitory effect.
4.4 Tumor cell specificity
As a next demonstration of the benefit of the cell-level pharmacokinetic/ pharmacodynamic
model we predicted the effect on cells with different alterations to determine how to optimize
the specificity of antibodies against tumor cells.
Upregulation of EGFR expression and aberrant activation of EGFR has been shown in
many human epithelial cancers, including those of the colon, lung, kidney, head and neck,
breast, prostate, brain and ovary[124, 105, 122, 149, 56, 142]. The extent of overexpression
also correlates with a poorer clinical outcome[95, 49].
To compare the response of normal and tumor cells to anti-EGFR antibodies, we extended
our model by integrating a kinetic cellular model representing tumor cells with elevated EGFR
levels (see Fig. 4.1(c)). The cellular model for the tumor cells was chosen to resemble the
characteristics of A431 cells, a human squamous carcinoma cell line with high EGFR levels
[91, 83, 145]. The overexpression in A431 cell is due to amplification of the EGFR gene[97] and
correlates with increased EGF receptor mRNA levels[83]. A431 cells express about 1.8 · 106
EGFR at the cell surface[91]. In vivo experiments are typically designed in a way that the
A431 tumors do not influence the pharmacokinetics of the mAbs (e.g., Bleeker et al.[13] in
mice). We therefore set the number of tumor cells to 1% of the normal cells, which had little
impact on the pharmacokinetics. The tumor cell model represents those tumor cells exposed
to drug concentrations equivalent to the exposure of cells with normal EGFR levels.
The extended cell-level pharmacokinetic/pharmacodynamic model was also used to study
whether cells with higher receptor levels are more susceptible to antibody treatment than
normal cells. Figure 4.4 (a) illustrates the predicted inhibitory effect in tumor and normal
cells in cynomolgus monkeys. For tumor cells with elevated receptor levels, the inhibitory
effect is seen to be stronger than for those cells with normal EGFR levels.
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Figure 4.4: The mechanism underlying increased receptor levels influences tumor specificity of mAbs.
(a) Predicted transient inhibition based on the extended cell-level pharmacokinetic model shown in
Figure 4.1(c) for normal cells ( ), tumor cells with a 10-fold increased receptor expression ( ), and
tumor cells with a 10-fold decreased internalization of the free and bound receptor ( ). Profiles are
shown for a high dose of 20 mg ( ) and a low dose of 2 mg ( ). Both scenarios show similar steady-
state activation levels of the receptor, but their response to drug treatment is substantially different.
(b) Antibody specificity as ratio of effect in tumor cells compared to cells with normal levels of EGFR
for the three effect characteristics. Cells with a decreased receptor internalization have a much longer
duration of inhibition and therefore a higher integral of inhibition than tumor cells with an increased
receptor expression.
Elevated receptor levels as potential biomarkers
The cell-level model (Fig. 4.1 (a)) suggests that elevated receptor levels can be a consequence
of not only an increased receptor expression, but also of a reduced internalization of the
receptor. Reddy et al.[113] reports about an alteration of EFGR where a truncated cyto-
plasmic domain exhibits a decreased ligand-induced internalization rate constant. Figure 4.4
(a) compares the predicted transient inhibition for both alterations, increased synthesis rate
and reduced internalization. Although both cell alterations resulted in similar steady-state
activation levels, their responses to mAbs are remarkably different.
For a quantitative comparison of the inhibitory effect in normal and tumor cells, we defined
the tumor specificity S as the ratio of the inhibitory effect on tumor cells relative to normal
cells. Thus we have
Speak =
peakt
peak
, (4.7)
Sduration =
durationt
duration
, (4.8)
SE =
Et
E
. (4.9)
We compared the tumor specificity tumor:normal, S for both types of alterations for a 20 mg
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dose of a high affine mAb (Figure 4.4(b)).
A 10-fold receptor overexpression in tumor cells resulted in the same amplification of the
integral of inhibition. Although the initial decrease is stronger in tumor cells overexpressing
the receptor, at the same time, due to the increased receptor expression, the recovery was
considerably faster and in total leads to the same duration of the inhibition as in normal cells.
In the case of overexpression, mAbs are selective only in terms of the integral of inhibition. As
supported by a theoretical analysis (Supplementary Material Section 6.3), mAbs specificity
holds independently of the model parameterization, mAbs target affinity, downregulation
constant and dose. Our findings therefore suggest that when considering the direct inhibitory
effect, the specificity of therapeutic antibodies against tumor cells overexpressing the receptor
cannot be improved by tuning the drugs properties.
Cells with decreased receptor internalization, in contrast, showed a higher integral and
duration of inhibition compared to normal cells. Also, since tumor specificity of mAbs for
cells with decreased internalization rates depends on the affinity and dose of the mAbs, further
optimization of their tumor specificity can be achieved by lowering affinity and/or dose.
4.5 Summary and Conclusions of this chapter
Mechanism-based pharmacokinetic and pharmacodynamic models constitute a scientific basis
for understanding drug efficacy and safety. Such models contribute to improving efficiency in
the drug development process and to reduce attrition rates [109]. In cynomolgus monkeys,
our cell-level pharmacokinetic/pharmacodynamic model predicts almost identical direct in-
hibitory effects for a range of antigen-binding affinities. Supporting theoretical analysis of the
model suggests that the existence of an effect plateau is a generic feature of this drug-target
system and does not depend on specific parameter values. Current anti-EGFR antibodies are
located on the effect plateau which relativizes the affinity amongst the properties that can
be further tuned to optimize antibody efficacy. In view of our findings, the recent assertions
that panitumumab, due to its very high affinity, can compete more effectively with ligands
for binding to EGFR compared to high affinity mAbs [61]; and that nimotuzumab, due to
its intermediate affinity, relies on the high number of receptors as present on tumor cells for
efficient binding [24], should be revisited.
Based on the existence of an effect plateau in the direct inhibitory effect, the clinically
observed differences among mAbs are likely to arise from indirect effects, such as the action
of immune effector functions (such as antibody dependent cell mediated cytotoxicity or com-
plement dependent cytotoxicity), rather than the direct antagonistic effect. This is consistent
with a study of Bleeker et al. showing that effects in vivo of zalutumumab and cetuximab
differed only by their ability to trigger such indirect effect and not by their direct inhibitory
effect [13].
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Regarding optimization of tumor specificity, we find that antibody specificity depends on
the tumor cell type, i.e., the alterations underlying elevated receptor numbers. Tumor cells
with an increased receptor expression seem to recover from the drug treatment faster than
those with reduced internalization rates, despite potentially presenting similar receptor num-
bers. Our analysis suggests that biophysical properties cannot be tuned regarding the speci-
ficity of the direct effect on tumor cells overexpressing the receptor (such as A431 cells). In
contrast, for tumor cells with a decreased receptor internalization, the specificity is increased
for lower affinity and/or dose. This increased specificity, however, comes along with a lower
absolute effect.
Using cutaneous toxicities—the most common side effects of anti-EGFR antibodies, affect-
ing 45–100% of patients [79]—as a marker of drug efficacy and clinical outcome was proposed
[108]. Clinical experience, however, has shown that EGFR levels, as measured by immuno-
histochemistry, do not predict clinical benefit [25, 21]. Our finding regarding the dependence
of drug efficacy on tumor type suggests that the unsatisfactory correlation between elevated
receptor levels and drug efficacy may be improved by a genotypic determination of the un-
derlying cellular alterations.
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Mathematical modelling has become a widely used methodology in preclinical drug discovery,
early clinical development, and later stage clinical development [2, 62, 162, 148, 80, 58, 18].
Mechanistic models of cell-level kinetics are of increasing importance for target identification
and validation [130]. Mechanistic models can describe the causal path between the drug
and the effect and also make an explicit distinction between drug specific and organism
specific parameters. A main challenge today is to integrate data and knowledge from different
sources such as clinical PK data, in vitro data, genomic studies, and bioinformatics to link
the exposure of a drug (or combination of drugs) and the modulation of pharmacological
targets, physiological pathways and ultimately disease systems [162]. This is the objective
of the arising field of systems pharmacology by considering targets in the context of the
biological networks in which they exist. In this thesis we developed an approach of combining
empirical pharmacokinetic and mechanistic cell-level models to bring the different areas closer
together. The model can act as a quantitative framework which allows to accumulate and
pool the knowledge over the different stages of the drug development pipeline.
Following the lessons we learned from modelling the nonlinear pharmacokinetics of thera-
peutic proteins, we want to raise the question if the nonlinear pharmacokinetics of therapeutic
proteins is a curse or a gift for analyzing clinical data and adjust dosing of the drug. Tra-
ditionally the nonlinearity is seen as a factor which complicates dose finding, and although
this might be true, we would argue that the nonlinearity can be well described and predicted
using nonlinear pharmacokinetic models, if the physiological reasons and mechanism are un-
derstood. Additionally, we are convinced that nonlinear pharmacokinetics occurring because
of the interaction of the drug with the target gives precious information about the action of
the drug, which can be further enriched by mechanistic modelling of cellular processes.
In a way, therapeutic proteins blur the traditional distinction between pharmacokinetics
and pharmacodynamics. Processes, such as the binding of the drug to the receptor, cannot
be classified either as only controlling the disposition or the effect of the drug, but influence
both at the same time. The development of modelling concepts like TMDD is a first step to
include cell-level processes like receptor binding and trafficking into pharmacokinetic models.
Nevertheless, we argue that defining the cell as the fundamental unit of the model, as is
done in systems biology, is for many applications an advantage over pooling processes on a
whole body level. As demonstrated in this thesis, a cellular model allows to mechanistically
describe processes, compare alterations in different cell types, and the global optimization
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of drug properties. Another aspect is that TMDD describes only processes such as target
turnover, drug binding, and the internalization of the drug-target complex. We learned in
Chapter 4 these processes alone might not allow to describe the pharmacokinetics of ther-
apeutic antibodies. As we saw for zalutumumab, the existence of an intracellular pool of
receptor (dynamically described by the internalization and recycling of the free receptor) can
be important. Only this pool in addition to the turnover of the receptor explained the ini-
tial decrease of drug concentration right after drug administration as well as the clearance
velocity in the terminal phase. This demonstrates how processes according to the knowledge
of the cellular level can be added to the pharmacokinetic model and might allow a better
explanation of data determined in clinical trials.
In the following, we will discuss possible extensions to the model. A limitation of the
proposed cell-level pharmacokinetic/ pharmacodynamic model is that predictions of EGFR
inhibition on tumor cells are limited to those malignant cells which are exposed to similar
concentration than normal cells, such as avascular metastases embedded in healthy tissue
[143]. In solid tumors, due to heterogeneous drug distribution, only malignant cells close
to capillaries might be exposed to such concentration. A more physiological description of
the pharmacokinetic model may allow to distinguish between the drug concentrations in the
different tissues or the tumor. One possible extension we identify, is therefore the use of
physiologically based pharmacokinetic models (PBPK).
The difference of PBPK compared to the empirical compartment models described in sec-
tion 2.2 is that compartments and volumes of PBPK models correspond to discrete tissues,
organs and other physiologically identifiable spaces. Further, the distribution of the drug in
the body is described by fluxes corresponding to the blood flows connecting the organs or
organ groups (see Fig. 5.1). In the different organs the distribution process is modelled in
terms of so called partition coefficients which describe the steady-state concentration within
the tissue compared to the blood concentration. Additionally to the physiologically based
“wiring” of the organs by the bloodstream each organ can be further divided into submodels
representing different subcompartments like the interstitial space or the cytosol of cells (see
Fig. 5.2). Using this framework, the tumor can be described as a single compartment or be
subdivided in different parts which are differentially accessible to the drug.
For describing the disposition of antibody drugs, PBPK models should incorporate the
particularities associated with antibody disposition such as convective movement of antibodies
into tissues, lymphatic circulation, RME, and catabolism in the different tissues [84, 141].
Several PBPK models for antibodies have been developed [10, 23, 36, 9, 42, 60, 164, 165, 43,
28, 52, 146]. In contrast to PBPK models for small molecules these models should include the
lymphatic system and usually also a submodel which describes the flux of macromolecules
from the blood capillaries to the interstitial space of the organs [117]. A two-pore model which
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Figure 5.1: Schematic structure of a physiologically based pharmacokinetic model (PBPK). The mod-
elled organs or organ groups are connected by the blood flow.
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Figure 5.2: A submodel in a PBPK model which describes the processes involved in the distribution
of antibodies inside a tissue.
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Figure 5.3: Schematic illustration of the two pore model describing the extravasation of antibodies.
describes this is depicted in Fig. 5.3. Another exceptional aspect of antibody disposition in the
body is binding to the neonatal Fc receptor (FcRn). FcRn contributes to effective humoral
immunity by recycling IgG and extending its half-life in the circulation [119]. FcRn binds
tightly to the Fc portion of IgG at acidic pH 6.0 in endosomes, but not at physiological pH
7.4 and therefore can recycle IgG back the circulation secondary to internalization by RME.
Because of its important role for the pharmacokinetics usually the FcRn is incorporated into
PBPK model for mAbs.
Because of their mechanistic nature, PBPK models in the future probably will play a key
role when aiming to include mechanistic pharmacodynamic models of mAbs [111]. PBPK
models together with mechanistic pharmacodynamic models of cellular processes have the
potential to account simultaneously for processes such as systemic distribution, extravasation
into tissue, lymphatic drainage, target binding, target dynamics, and metabolisation of mAbs.
The advantage of a more detailed description of the pharmacokinetics comes with the
need for many parameters and detailed drug concentration data from different compart-
ments/tissues for a validation of the model. This limits the use of PBPK models in the
analysis of sparse clinical data where usually only drug concentrations in plasma are deter-
mined. This was the reason why we used empirical compartment models to describe the
pharmacokinetics in this thesis. Moreover, it is known that the main space of antibody dis-
tribution is the plasma and the interstitial space. Hence, the used two-compartment model
seems physiologically and pharmacokinetically motivated. Nevertheless, in the cases where
detailed measurements of drug concentrations from different organs are available (like it might
be the case for preclinical studies in animal models) PBPK models might be a rational basis
for the integration of cellular models such as the ones described in this thesis.
A further limitation of the current cell-level pharmacokinetic/ pharmacodynamic model is
that it predicts decrease in receptor activation instead of the actual biological response of the
cell. While Knauer et al. [68] reported a linear dependence between the number of activated
EGFR at steady-state and the cellular responses of fibroblasts and epithelial cells, other
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models describe a more complex relationship between receptor activation and downstream
signaling [129]. A possible extension of the cell-level pharmacokinetic/ pharmacodynamic
model is therefore the integration of more detailed cell-level models.
Additionally to the receptor activation models discussed in Section 3.1, many very detailed
systems biology models of receptor activation, trafficking and downstream signalling have been
developed. Schoebel et al. [129] derived and validated a comprehensive model of 94 ordinary
differential equations with 95 parameters connecting the activated EGFR to the downstream
kinase ERK (Extracellular signal–Regulated Kinase). The model provides insight into the
high robustness of the downstream signalling of EGFR, where over a range of 100 fold ligand
concentration the activation of ERK seems to be remarkably stable. The important parameter
for signal efficacy is the initial velocity of receptor activation and this is mainly determined
by the affinity of the ligand.
Studying the input-output behavior of the EGFR signalling network became even more
detailed when Birtwistle et al. [11] and Chen et al. [20] included also the activation and
signalling of the other cell surface receptors of the ErbB/Her family. Birtwistle found that the
overexpression of the receptor ErbB2 leads to change in the activation of ERK over time. The
overexpression transformed a transient activation of the cell-surface receptors into a sustained
activation of the ERK. Chen et al. eluminated the dependence of the signalling behavior on the
conditions (which ligand binds to the cell surface receptors) and the feature (the downstream
effector kinase which gets activated). Very recently, the model of the signalling of the ErbB
family has been further extended to study the crosstalk between the signalling downstream
of the EGFR and the Insulin receptor [14].
Our approach to couple systems biology models with pharmacokinetic models in general
allows for integrating such detailed models of downstream signalling into systemic pharma-
cokinetic models. To couple such detailed downstream signalling models, the cell-level model
has to provide the species which act as an interface between the signalling inside the cell and
the receptor dynamics on the cell surface. For example, models which describe the activation
of the different receptors of the ErbB family[11, 20] would need a more detailed receptor ac-
tivation and inhibition model than the ones we developed in this thesis. On the other hand,
models of EGFR downstream signalling where the free EGF receptor at the cell membrane
is already part of model (like, e.g., the comprehensive model of Schoeberl et al. [129]), may
allow a direct coupling with our developed cell-level PK/PD model.
In conclusion, we propose that detailed cell-level models combined with pharmacokinetic
models will prove valuable in the emerging field of systems pharmacology. Further, the use of
more detailed systems biology models describing downstream signaling processes relevant to
human diseases [20, 14, 63] may allow to translate a drugs’ plasma concentration into receptor
activation and ultimately into a biological responses of tumor cells.
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6.1 Derivation of an exact formula for the inhibitory effect
We consider the model defined in Eq. (3.2) and define the steady state as R∗, RL∗, RD∗ and
D∗ = 0. The integral of the inhibitory effect is defined as
E =
∫ ∞
0
RL(t)−RL∗ dt. (6.1)
We rewrite model (3.2) in terms of the deviations of the species from their steady state values.
We define these deviation variables as
R¯(t) = R(t)−R∗, D¯(t) = D(t)−D∗,
R¯D(t) = RD(t)−RD∗, R¯L(t) = RL(t)−RL∗,
and the state vector as
x¯(t) =
[
D¯(t) R¯(t) R¯L(t) R¯D(t)
]T
. (6.2)
A taylor expansion around the steady state x∗ gives
dx(t)
dt
= Nv(x, t) |x=x∗ +N d
dx
v(x, t) |x=x∗ x¯+ 1
2
x¯TN
d2
d2x
v(x, t) |x=x∗ x¯ (6.3)
Because
d x¯
dt
=
dx(t)
dt
− d x¯
dt
=
dx(t)
dt
(6.4)
and
Nv(x, t) |x=x∗= 0 (6.5)
it follows that the resulting system of ODEs in terms of the new state variable is given by
d x¯
dt
= Ax¯(t) +Bx¯1x¯2, (6.6)
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where the matrix A = N ddxv(x, t) |x=x∗∈ R4×4 is the Jacobian of the right hand side of (3.2)
evaluated at the steady state
A =

−konDR∗V Na 0 0
koffD
V Na
−konDR∗ −konLL− kdegR koffL koffD
0 konLL −koffL − kdegRL 0
konDR
∗ 0 0 −koffD − kdegRD
 , (6.7)
and
B =
[
konD
V Na
konD 0 −konD
]T
. (6.8)
Integration of (6.6) from t = 0 to infinity gives
x¯(∞)− x¯(0) = A
∫ ∞
0
x¯(t)dt+B
∫ ∞
0
x¯1(t)x¯2(t)dt. (6.9)
For a bolus dose C at t = 0 the initial condition for (6.6) is
x¯(0) =
[
C 0 0 0
]T
. (6.10)
Under the biologically reasonable assumption that when the drug disappears the receptor
system goes back to its old steady-state activation level (described in Section 3.2), the stability
of the system implies that x¯(∞) = 0. Substitution in (6.9) yields∫ ∞
0
x¯(t)dt = A−1x¯(0) +A−1B
∫ ∞
0
x¯1(t)x¯2(t)dt. (6.11)
From (6.1) and (6.2) we notice that E =
∫∞
0 x¯3(t)dt, that is,
E =
[
A−1B
]
3
+
[
A−1x¯(0)
]
3
. (6.12)
Computing A−1 it can be shown that
[
A−1B
]
3
= 0 and (6.12) leads to
E = V NaC
konLL
LkonLkdegRL + kdegRkoffL + kdegRkdegRL
. (6.13)
From model (3.2) the steady state concentration RL∗ is given by
RL∗ =
konLkRL
LkonLkdegRL + kdegRkoffL + kdegRkdegRL
. (6.14)
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Combining (6.14) with (6.13) finally yields a simple formula for the cumulative effect
E =
V NaRL
∗
kR
C. (6.15)
Assume tend to be the length of the treatment period and sufficiently large so that
E =
∫ ∞
0
(RL∗ −RL(t)) dt ≈
∫ tend
0
(RL∗ −RL(t)) dt. (6.16)
Then the relative inhibitory effect can be expressed as
Er =
∫ tend
0 (R
∗
L −RL(t)) dt∫ tend
0 R
∗
L dt
=
V NaCR
∗
L
tendkRR
∗
L
=
V NaC
tendkR
=
dose
tendkR
. (6.17)
6.2 Quantification of the integral of effect in vivo
The steady state of model (4.1)-(4.3) is
x∗ =
[
D∗p D∗c R∗ R∗i RL
∗ RD∗ R∗t Ri∗t RL∗t RD∗t
]
,
and we know that D∗p = D∗c = RD∗ = RD∗t = 0. We assume that the steady state is
exponentially stable, which for any realistic scenario is trivially satisfied. This guarantees
that the integral of the inhibition
E =
∫ ∞
0
(RL∗ −RL(t)) dt, (6.18)
is a finite number. The deviations of the model variables with respect to the steady state are
R¯ = R∗ −R R¯t = R∗t −Rt D¯p = −Dp
R¯i = R
∗
i −Ri R¯it = Ri∗t −Rit D¯c = −Dc
R¯L = RL∗ −RL ¯RLt = RL∗t −RLt
R¯D = −RD ¯RDt = −RDt
We define a state vector as
x¯ =
[
D¯p D¯c R¯ R¯i R¯L R¯D R¯t R¯it ¯RLt ¯RDt
]T
. (6.19)
The model is linearized around the steady state. This leads to the following linear system of
ODEs
d x¯
dt
= Ax¯. (6.20)
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The matrix A ∈ R10×10 is given in (6.7) and corresponds to the Jacobian of the right hand
side of (4.1)-(4.3) evaluated at the steady state. Integration of (6.20) from t = 0 up to t =∞
gives
x¯(∞)− x¯(0) = A
∫ ∞
0
x¯(t)dt. (6.21)
For a bolus dose C at t = 0 the initial condition for (6.20) is
x¯(0) =
[
−C 0 0 · · · 0
]T
. (6.22)
As before, the return to the old steady-state activation level of the receptor after the drug
disappears implies that x¯(∞) = 0, which upon substitution in (6.21) yields∫ ∞
0
x¯(t)dt = −A−1x¯(0). (6.23)
From (6.19) we notice that the integral of inhibition E is the 5th entry of the vector in (6.23).
Hence
E =
∫ ∞
0
x¯5(t)dt = −
[
A−1x¯(0)
]
5
. (6.24)
Computing the inverse A−1 we get
E =
αRL∗
β + γ 1konD
(
1
CP + 1
) , (6.25)
with the constants:
α = VcR
∗qcpC
kdegR
konLL
(
koffL + kdegRL
krecyR + kexit
)
, (6.26)
β = kRhSF(qcp + CLlinD)(NhR
∗ +NtR∗t ), (6.27)
γ = kRhCLlinDqpc. (6.28)
The parameter KD = 1/affinity and the “consumption parameter” defined by Shankaran et
al. [133] are given by
KD =
koffD
konD
CP =
kdegRD
koffD
. (6.29)
The effect E is a decreasing function of koffD and shows little variations for the values of KD
for the mAbs in Table 4.3. All these mAbs are located in a plateau region of the effect E.
This linear analysis suggests that the effect plateau is a structural feature of the system and
does not depend on the parameter values.
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6.3 Effect of receptor overexpression on the drug specificity
From the model (4.2)-(4.3), the ODEs for the free and bound receptors in the tumor cells are
dRt
dt
= kRt − konLRt · L− konDRt ·Dp + krecyRRit
+ koffLRLt + koffDRDt − kdegR ·Rt,
dRit
dt
= kdegR ·Rt − krecyR ·Rit − kexit ·Rit,
dRLt
dt
= konLRt · L− koffLRLt − kdegRLRLt,
dRDt
dt
= konD ·Rt ·Dp − koffDRDt − kdegRD ·RDt.
(6.33)
We assume that the tumor cells have a receptor synthesis rate that is α times higher than
in normal cells, i.e., kRt = αkRh. Since the equilibrium values R
∗
t , Ri
∗
t , RL
∗
t and RD
∗
t are
proportional to kRt, we have that
R∗t = αR
∗, Ri∗t = αR
∗
i , (6.34)
RL∗t = αRL
∗, RD∗t = αRD
∗. (6.35)
Substituting kRt = αkRh in (6.33) and dividing by α yields
d
dt
(
Rt
α
)
= kRh − konLRt
α
· L− konDRt
α
·Dp + krecyRRit
α
+ koffL
RLt
α
+ koffD
RDt
α
− kdegR · Rt
α
,
d
dt
(
Rit
α
)
= kdegR · Rt
α
− krecyR · Rit
α
− kexit · Rit
α
,
d
dt
(
RLt
α
)
= konL
Rt
α
L− koffLRLt
α
− kdegRLRLt
α
,
d
dt
(
RDt
α
)
= konD · Rt
α
·Dp − koffDRDt
α
− kdegRD · RDt
α
.
. (6.36)
By comparing the ODES in (6.36) with those for the normal cells in (4.2), we see that receptor
overexpression translates into scaled responses in the tumor cells (note that according to
(6.34)-(6.35) the initial conditions are also scaled), i.e.,
Rt(t) = αR(t), Rit(t) = αRi(t),
RLt(t) = αRL(t), RDt(t) = αRD(t).
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The definitions of Speak, Sduration and SE in Section 4.4 lead to
Speak = 1, (6.37)
Sduration = 1, (6.38)
SE = α. (6.39)
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